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ABSTRACT OF THE THESIS
Breathlessness Descriptors in Patients with Chronic Obstructive Pulmonary Disease
versus Congestive Heart Failure
by
Adelaide de Souza Caroci
Master of Science, Graduate Program in Nursing
Loma Linda University, December 2001
Dr. Lois Van Cleve, Chairperson
This cross-sectional descriptive study investigated breathlessness (dyspnea) in
stable patients with Chronic Obstructive Pulmonary Disease (COPD) and Congestive
Heart Failure (CHF). The purpose of this study was (a) to characterize the most common
terms COPD and CHF patients use to describe their breathing, (b) to identify the
frequency of dyspnea in patients with COPD and CHF, and (c) to determine the intensity
of dyspnea in these populations.
A purposive sample of 60 patients, 30 with moderate to severe COPD and 30
patients with moderate to severe CHF, met the inclusion criteria and were enrolled in this
study. The participants provided subjective information about their breathing discomfort
by answering the Demographic Questionnaire and (b) Interview questionnaire developed
by the researcher, (c) Endorsing terms from a list of descriptors, and (d) General dyspnea
questionnaire from the Pulmonary Function Status and Dyspnea Questionnaire. Data was
collected in an outpatient Pulmonary and CHF clinic of a Medical Center.
The results indicated that patients with COPD and CHF chose different the terms
to describe their breathing discomfort. There was no significant difference between the
incidence (x2 = 2.080, p = .195) and frequency (t = 0.270, p = .788) patients
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with COPD and CHF experience dyspnea. Participants with COPD reported significantly
more dyspnea intensity ()than CHF in three different situations (COPD:CHF):
(a) “past year” (f= 2.426, p

.018), (b) “today” (t = 2.459, p = .017), (c) most day-to-day

activities COPD (t = 2.499, p = .015 ).
The findings support the notion of previous studies regarding the breathlessness
descriptors. Individuals with certain health conditions use (a) terms that are unique to
describe their breathing experience, (b) choose more than one term (c) and use similar
terms to describe their breathing experience. This study identified affective descriptors
were among breathlessness descriptors in both groups. The frequency and intensity of
dyspnea among COPD and CHF, had not been reported in previous studies, were
identified.

INTRODUCTION
Dyspnea or breathlessness is perhaps the most common symptom reported by
patients with Chronic Obstructive Pulmonary disease (COPD) and Congestive Heart
Failure (CHF) patients (Simon et ah, 1990; Carrieri-Kohlman, Gormley, Douglas, Paul &
Stulbarg 1996; Wilson, Hanamanthu, Chomsky & Davis 1999). Even though patient
reports of dyspnea are often used to make clinical judgments, there are limited studies
addressing the terms COPD and particularly CHF patients select to describe their
breathing.
Patients with respiratory and cardiovascular diseases account for approximately
two-thirds of all cases of dyspnea (Mahler et al. 1996, p. 1357). While the incidence of
dyspnea in COPD and CHF has not been reported, estimates are commonly made based
on the prevalence of the diseases causing this symptom (Carrieri-Kohlman & JansonBejerklie,1993).
COPD is one of the leading causes of morbidity, mortality, and economic burden
around the world (Sullivan, Ramsey & Lee, 1999; Chen & Mannino, 1999). The 1996
survey by the National Health Interview Survey (NHIS) estimated the prevalence of
COPD in the United States at 16 million (ALA [American Lung Association], 2000a).
The cost of care for COPD patients in the United States was $26 billion in 1998.
According to the ALA, COPD was responsible for 103,595 deaths which represents 4.7%
of the total number of deaths in the United States (ALA, 2000b).
The American Heart Association (AHA) reported there are 4,600,000 patients
with CHF in the United States, with 550,000 new cases of CHF each year, with a
mortality of 45,419 cases a year. The estimated cost of caring for CHF patients in the
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year 2000 was $22.5 billion. From 1979 to 1997, deaths from CHF increased by 127.8%
(AHA, 2000).
These figures suggest that COPD and CHF alone, account for substantial
disability, loss of life and financial burden in the United States. It also provides an
estimate of the number of individuals that experience dyspnea (approximately 20
million). Providing appropriate and timely treatment of these patients depends on
effective clinical decision making skills. Although dyspnea is a predominant symptom in
the COPD and CHF populations, the terms or descriptors patients use to communicate
their dyspnea are still poorly understood. A clear understanding of the terms used by
COPD and CHF patients to describe their breathing, may provide additional guidance for
clinicians in determining how the disease affect the breathing of this population and
subsequent treatment.
Purpose
The purpose of this study is to determine if differences exist between reports of
dyspnea in COPD and CHF patients by: (a) characterizing the most common terms used
to describe their breathing, (b) identifying the frequency of dyspnea and (c) determining
the severity of dyspnea in patients with COPD and CHF.
Research Questions
The research questions for this study are: 1) What are the most common terms
COPD patients use to describe their breathing discomfort? 2) What are the most common
terms CHF patients use to describe their breathing discomfort? 3) Is there a difference in
the terms COPD and CHF patients use to describe their breathing discomfort? 4) What is
the frequency of dyspnea in COPD patients? 5) What is the frequency of dyspnea in CHF
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patients? 6) What is the intensity of dyspnea in patients with COPD? 7) What is the
intensity of dyspnea in patients with CHF?
Significance to Nursing
Patients with pulmonary and cardiac conditions use various terms to describe their
symptoms. These terms may relate to shortness of breath, pain, fatigue, or nausea. In the
COPD and CHF populations, shortness of breath is commonly used by patients to
describe dyspnea, but does the term “shortness of breath” truly describe the breathing
discomfort experienced by patients with COPD and CHF?
Nurses and other health care providers often make clinical judgments about
worsening or improvement in the patient’s condition, based on patient reports. Although
technology has led professionals to rely on diagnostic tests to diagnose various
conditions, most of the information health professionals acquire about medical problems
comes from patient histories (Schwartzstein, 1999). By understanding the terminology
that represents the experience of this population, better communication, assessment, and
treatment of patients with dyspnea may occur. Considering the impact of dyspnea on the
COPD and CHF populations, this study aims to bring useful knowledge that may benefit
both patients with these conditions as well as their health care providers.
Definitions
In this study, the following definitions of terms are used:
Chronic Obstructive Pulmonary Disease (COPD) - COPD is defined as “a disease state
characterized by the presence of airflow obstruction due to chronic bronchitis or
emphysema; the airflow obstruction is generally progressive, may be accompanied by

3

airway hyperreactivity, and may be partially reversible.” (American Thoracic Society
[ATS], 1995, S78)
Congestive Heart Failure (CHF) - CHF “is a clinical syndrome manifested by
characteristic symptoms and signs, none of which are specific, caused by an
abnormality(ies) of ventricular function resulting in the inability of the heart to deliver
adequate cardiac output at normal filling pressures at rest or during exercise”(Krumholz
et al. (2000, p.l).
Dyspnea, breathlessness: The term dyspnea and breathlessness are used interchangeably
(Howell & Campbell, 1966; Carrieri, Janson-Bjerklie & Jabobs,1984; Simon et. al, 1989;
Mahler et al., 1996). Some definitions of dyspnea address either the physical or
emotional aspects separately. Dyspnea or breathlessness has been defined as “distressful
sensation of uncomfortable breathing” (Mosby, 1998, p.749), “uncomfortable awareness
of breathing”, or (Simon et al., 1989, p.l 021) “a general term used to characterize a range
of qualitative distinct sensation” (Moy, Lantin, Harver & Schwartzstein 1998, p.349).
Recently a recognized international society of pulmonary experts proposed a
broader definition of dyspnea that portrays an understanding of the interplay between the
physical, behavioral, and personal factors that influence the dyspnea sensation:
Dyspnea is a term used to characterize a subjective experience of breathing
discomfort that consists of qualitatively distinct sensations that vary in intensity.
The experience derives from interactions among multiple physiological,
psychological, social, and environmental factors, and may induce secondary
physiological and behavioral responses (ATS 1999, p. 322).
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The present study will approach dyspnea according to the definition suggested by
this recent statement by the ATS by acknowledging the multiple aspects that influence
this symptom.
Dyspnea or breathlessness descriptors - This term will be used to identify the terms that
patients use to describe their breathing as opposed to the terms reported in the literature
(e.g. Simon et ah, 1989; Mahler et ah, 1996). These terms will be identified by asking
patients to report in their own words, what term(s) they use to describe their breathing
when it is uncomfortable (Appendix B). Also, patients will select from a list of
descriptors revised by Simon et al. (1990), the phrases that best describe their breathing
experience (Appendix C).
Endorsed Descriptors - Descriptors selected by either COPD or CHF patients from a
predetermined list of descriptors.
Frequency - The frequency of dyspnea indicates the number of times patients experience
severe to very severe dyspnea in a one month period. The dyspnea component of the
PFSDQ (Pulmonary Functional Status and Dyspnea Questionnaire- Appendix A) will be
used to determine how often patients experience dyspnea (Lareau, Carriery-Kohlman,
Janson-Bjerklie, & Roos, 1994).
Hypercapnia - An increase in carbon dioxide levels.
Hypoxia - A decrease in oxygen levels.
Intensity - Intensity of dyspnea is the degree of severity of dyspnea on a zero to 10 scale
from the PFSDQ questionnaire. In this questionnaire, patients rate their shortness of
breath for three different situations: (1) their dyspnea on most days during the past year,
(2) with most day to day activities and (3) the day of the interview. Severity is rated from
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0 (no shortness of breath) to 10 (very severe shortness of breath).
Shortness of Breath - This term has been frequently used in the literature as a descriptor
of dyspnea or breathlessness (Howell & Campbell, 1966; Simon et al, 1989, Simon et
ah, 1990). In this study the terms shortness of breath, breathlessness, and dyspnea will be
used interchangeably except when describing the exact words reported by patients to
describe their breathing.
Qualitative or Subjective aspects of dyspnea - Qualitative or subjective aspects of
dyspnea are terms that will be used interchangeably in this study. These terms refer to
factors that trigger dyspnea symptom which are not easily measured such as behavior and
emotions.
Volunteered Descriptors - exact words patients use to describe their breathing
discomfort.
Conceptual Framework
Dyspnea has been defined as the subjective experience of breathing discomfort
affecting the individual as a whole. It derives from the interaction among multiple factors
and responses: physiological, psychological, social, and environmental factors, and may
induce secondary physiological and behavioral responses (ATS 1999, p. 322). Because of
the complexity of dyspnea, its management is a challenge to health care providers,
patients with chronic conditions, caregivers and family.
The Symptom Interpretation Model (SIM) was utilized as conceptual framework
for this study (Figure 1). The SIM has been chosen because it represents symptom
interpretation as a multidimensional process expanding previous models of symptom
interpretation such as the UCSF Symptom Management Model and Leventhal models
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(University of California, San Francisco School of Nursing Symptom Management
Faculty Group, 1994, Leventhal, 1986). The key theories that contributed to the
development of the SIM are: (a) common sense representation of illness model by
Leventhal, Meyer, and Nerenz; (b)Barsalou’s theory of knowledge structures, and (c)
Tvensky and Kahneman’s propositions about reasoning (Teel, Meek, McNamara, &
Watson, 1997).
Figure 1
Adaptation of Symptom Interpretation Model

INTERPRETATION

INPUT

OUTCOMES

Memory past dyspnea
(descriptors, frequency &
intensity)
Dyspnea

t
Comparison
Judgments

Past year
Most days
Today

t

►

Dyspnea Descriptors

t
Intensity & frequency

L
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Seek Treatment
Follow Up:
Pulmonary &
CHF clinics

The SIM has expanded the concept of earlier models by introducing the reasoning
component that provides a better understanding of symptom representation and the
reasoning that lead patients to action (Appendix D). This model “...addresses how
individuals determine whether symptoms are familiar and whether actions are required in
response to the symptom experience.” (Teel et al. 1997, p. 29) The concepts introduced
by the SIM are the process of symptom interpretation and the reasoning that prompt
patients to make decisions about their health and treatment. In the SIM, symptoms are
understood as an important component of the illness but not its main part (Teel et al.,
1997).
Constructs of the Symptom Interpretation Model
The constructs of the SIM are: 1) input; 2) interpretation with its subsections:
conceptual identification, knowledge structures, and reasoning; and 3) outcome (Teel et
al., 1997, p.176). Figure 1 shows the Adaptation of the Symptom Interpretation Model as
it would related to the understanding of dyspnea in the stable COPD and CHF
populations. Further application of this model to the study population will be described in
the following paragraphs.
Input
Important internal or external changes in the individual’s environment cause
disturbances that stimulate an “awareness that something is different”. Input “represents
the interaction between environmental disturbance and awareness” (Teel, et al., 1997,
p.176-177). This construct acknowledges the influence of the internal and external
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stimuli individuals experience with dyspnea and is consistent with the multiple factors
that may trigger dyspnea in the COPD and CHF populations.
Some of the stimuli which trigger dyspnea in the COPD and CHF populations are:
(a) the pathophysiologic conditions of COPD and CHF that causes “increased effort or
work” and lead to dyspnea due to the “mismatch between central respiratory motor
activity and incoming afferent information from receptors in the airways, lungs, and chest
wall structures.” (ATS, 1999, p.323- 325), (b) emotions, (c) individual factors such as
culture, age and gender, and (d) current context (e.g. acute episodes or exacerbations of
the disease or stable).
Interpretation
The second component of this model is “interpretation” which follows the
individual’s awareness of the changes that are taking place. The model proposes that
several key factors play a role in this evaluation process such as the patient’s memory for
past symptoms, a comparison of the current experience with known experience and
labeling the symptom. Labeling the symptoms is the focus of this study since it aims to
understand the terms that are the “labels” patients use to “name” their symptom. In the
interpretation phase, individuals recognize, categorize, and evaluate the stimuli through
three elements:
1. Conceptual Identification refers to the process by which the individual
“names” the symptom is called “conceptual identification” in this model. Patients use
their reasoning and knowledge structure to attribute meaning to their symptom. This is
done by establishing a relationship between the stimuli at the input phase with previous
knowledge or experiences.
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2. Knowledge Structures are knowledge base that individuals utilize for the
interpretation of their symptoms. Although the specific knowledge structure of symptom
interpretation is unclear, the SIM emphasizes two knowledge structures that more clearly
used: exemplar and prototypes. Exemplar represents interpretation based on concrete past
experiences while prototypes represents central tendencies of past experiences.
Prototypes are more frequently used in the symptom interpretation than concrete
structures of knowledge. Thus, prototype is the knowledge structure that seem to best
represent the experience of patients with chronic symptoms such as dyspnea. When
applying the prototype knowledge to understand dyspnea in the COPD and CHF
population, it is assumed that this population has stored in their memory knowledge and
experiences with dyspnea. When experiencing new symptoms patients access their
previous knowledge or experience. This knowledge that records the central tendencies of
the dyspnea will be used as the basis for comparison against the “incoming symptom”.
The study will assess the usual or typical quality, intensity, and frequency of dyspnea as
the knowledge structure.
3. Heuristic reasoning entails a systematic reasoning based on self-teaching
strategies. Patients use judgment heuristics to compare similarities between an event and
the categorized information based on their knowledge and previous experiences (Teel et
al., 1997). By using the heuristic reasoning, COPD and CHF patients will compare the
intensity of their dyspnea on “most days”, during the past year, and on the day of the
interview. This study assumes that the participants, who are stable, will report terms that
describe their unusual or uncomfortable sensation of breathing which may reflect past or
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recent experiences instead of reporting experiences that reflects the exacerbation of their
disease.
Output
The third component of the model comprises the individual’s choices after the
interpretation process. These choices may include action or no action (Teel et ah, 1997,
p.178). Since all patients will be enrolled in the Pulmonary or CHF clinics, this study
assumes that these patients went though the process of interpretation and reasoning
suggested by this model. The interpretation of the intensity of dyspnea experienced by
these patients may have been the main symptom that brought these patients to seek health
care. Independent of the stimuli that caused them to seek health care, it is clear that these
patients chose to take action towards their symptom. Research suggests that changes in
the patient’s interpretation of symptoms, such as individual’s perception of changes in
severity, may have influenced the health care seeking behavior in heart failure patients
(Friedman, 1997).
Finally, the holistic approach of the SIM is consistent with the current definition
of dyspnea (e.g. ATS, 1999). Through a better understanding of the processes patients
may use to interpret and seek treatment patients with COPD and CHF, caregivers and
health providers may be able to manage dyspnea more successfully in these populations.
Organization of the Remainder of the Study
This thesis presents a description of the terms stable patients with COPD and
CHF utilize to describe their breathing discomfort and, characterizes the severity and
frequency these patients experience this symptom. Chapter 1 provided a general
introduction to the study including a statement of the problem, the purpose of the study,
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the research questions, the significance for nursing and the conceptual framework. The
literature and related studies are discussed in Chapter 2. Chapter 3 consists of Methods
and Materials and for data analysis. Chapter 4 presents results of the study. Chapter 5
presents the discussion and conclusions sections of the study, limitations, and future
research recommendations.
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REVIEW OF LITERATURE
This section reviews the literature on dyspnea. It addresses the pathophysiology of
dyspnea, dyspnea in the COPD population, dyspnea in the CHE population, qualitative
aspects of dyspnea, the language of breathlessness and ends with a summary and critique
subsection. Dyspnea may occur in pulmonary or cardiac disease, anemia, on maximal
exercise, with environmental stimuli, neurological deficiencies, cancer, and with anxiety
or stress (ATS, 1999; Ley, 1999; Teel et al. 1997, Carrieri-Kohlman et al. 1996). Most
individuals experiencing dyspnea have cardiac or pulmonary disease (Mahler et al. 1996;
Carrieri-Kohlman, Janson-Bjerklie & Jacobs, 1984).
Pathophysiology of Dyspnea
Studies have suggested that the sensations of dyspnea are created with the
activation of sensory systems and that more than one system is involved in this process
(Manning and Schwartzstein, 1995). The most recent definition of dyspnea,
acknowledges the multiple factors influencing the perception of this symptom having the
“homeostatic system as a framework:
Dyspnea results from a disassociation or a mismatch between central respiratory
motor activity and incoming afferent information from receptors in the airways,
lungs, and chest wall structures.” However, even though conditions such as
COPD and CHF may cause dyspnea, due to the same concept “increased effort or
work” resulting from the mismatch, the sensations experienced by these patients
seem to be different (ATS, 1999, p.323- 325).
Because of the multiple factors that contribute to dyspnea, the precise pathway(s)
of this symptom has not been clearly understood. Two mechanisms explaining the most

13

commonly accepted theories about the dyspnea pathway are the mechanoreceptors or
respiratory motor command, and the chemoreceptors (ATS, 1999, Manning &
Schwartzstein, 1995).
Mechanoreceptors
The mechanoreceptors are sensors located in the: (a) upper airway, (b) lung, and
(c) chest wall. These sensors respond to changes in length, tension or movement while
the chemoreceptors respond to changes in the levels of hydrogen, oxygen and carbon
(Manning & Schwartzstein ,1995, p.1549-1550; Caruana-Montaldo, Gleeson & Zwillich,
2000).

Upper airway receptors. Clinical observations have suggested that upper airway
receptors play a role in the sensation of dyspnea. A study addressing the role of upper
airway receptors on breathing indicated that patients notice improvement in dyspnea
when they are close to a fan or window (Schwartzstein et ah, 1987; Simon et ah, 1991).
While the mechanisms causing the improvement in dyspnea by stimulation of upper
airway receptors are unclear, these studies seem to support the role the upper airway
receptors may play in influencing the patient’s perception of dyspnea.
Lung receptors. Lung receptors have been shown to transmit information to the
central nervous system. Research has suggested that changes in the lung tissue caused by
inflation, mechanical and chemical changes, stimulate receptors in the airways leading to
dyspnea (Manning and Schwartzstein, 1995). Additionally, the role of the pulmonary
vagal receptors in mediating dyspnea have been acknowledged (ATS, 1999; CaruanaMontaldo, Gleeson & Zwillich, 2000).
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Chest wall receptors. Studies have suggested that chest wall mechanoreceptors
play a role in mediating sensations of dyspnea (Manning & Schwartztein, 1995).
According to Caruana-Montaldo et al. (2000), the primary receptors in the chest are
muscle spindle endings, tendon organs, and joint proprioreceptors. Muscle spindles
respond to muscle stretching by reflex contraction; tendon organs, are sensitive to
changes in the force of contraction of respiratory muscles and respond by inhibiting
inspiration and monitoring the force of muscle contraction; joint proprioreceptors are
sensitive to chest wall movement and affect respiratory rate. Additionally, vibration
appears to stimulate mechanoreceptors in the chest wall. The application of vibration on
chest wall has been shown to improve dyspnea in patients at rest and during exercise. It is
believed that by stimulating these receptors, the signals sent to the brain produce the
sensation of chest expansion and relieve dyspnea (ATS, 1999; Sibuya et al., 1994).
Chemoreceptors.
There are two major types of chemoreceptors; the peripheral and central
chemoreceptors Peripheral chemoreceptors are located at the carotid and aortic bodies
and central chemoreceptors, are located in the brainstem.
Carotid and aortic bodies, respond to changes in the concentration of hydrogen
ions (H+), Partial Pressure of Carbon Dioxide (PaCOi) and Partial Pressure of Oxygen
(Pa02). For instance, study has shown that arterial hypoxemia and acidosis increased tidal
volume (depth of breathing) in normal subjects. Changes in the concentration of H+,
PCO2, and Pa02 stimulate reflexes from the carotid bodies that are critical for
maintaining an appropriate level of these gases and ions in the organism. (Gonzalez,
Almaraz, Obeso, & Rigual, 1992).
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Central chemoreceptors are primarily sensitive to alteration in the levels of
hydrogen ions in the cerebrospinal and medullary interstitial fluid which are affected by
the C02 concentration. Elevated concentration of hydrogen ions stimulates respiration
while a decreased PaC02 inhibits (Caruana-Montaldo, et ah, 2000).
Other studies have supported the role of chemoreceptors on breathing. Corfield et
al. (1995) found carbon dioxide stimulates breathing by “almost four times” in normal
subjects at rest (p.83). Hypercapnia and hypoxia have been shown to affect the breathing
of subjects that have received neuromuscular blocking agents and patients with high
cervical cord transection suggesting that breathing is not affected solely by spinal nerve
innervation. Elevated levels of carbon dioxide have been shown to cause patients to
experience air hunger (Banzett, et al.,1989, Banzett, Lansing, & Brown, 1990). Further,
oxygen therapy has been shown to reduce breathlessness in some patients with lung
disease (Swinbum, Mould, Stone, Corris, & Gibson, 1991) and benefit CHF patients with
dyspnea (ATS, 1995).
Dyspnea in the COPD Population
According to Colt and Bergin (1999), “COPD is still a poorly understood term by
patients, the public and health care alike.” (p.194) COPD is a term used that may include
pulmonary emphysema, chronic bronchitis, or asthma. Considering the different
manifestation of asthma, the ATS has qualified that the asthma under the COPD
category, refer only to patients with chronic, unremitting asthma (ATS, 1995, p.78).
Chronic bronchitis, emphysema, and asthma are the primary diseases causing COPD,
which are characterized by a decrease in the forced expiratory volume (FEV). Decreased
expiratory volume, or airway obstruction can be measured by pulmonary function tests.
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Airway obstruction is often manifested by symptoms of dyspnea (Colt & Bergin, 1999;
Travis, Farber & Rubin, 1998).
Chronic bronchitis is defined as “the presence of chronic productive cough for 3
months in each of two successive years in patients in whom other causes of chronic
cough have been excluded.” (ATS, 1995, p. 78) The productive cough has been attributed
to hyperplasia and hypertrophy of mucous glands in the submucosa of the bronchi.
Causes of the changes have been reported as: respiratory infections, air pollution,
occupational exposure, gastroesophageal reflux, genetic disposition, and cigarettes
smoking. Of these, smoking seems to be the most common cause of chronic bronchitis
(Colt & Bergin, 1999; Travis et al., 1998). With the progression of the symptoms of
chronic bronchitis, patients may develop dyspnea, cyanosis, and cor-pulmonale (Travis et
al., 1998, p.625).
Emphysema has been defined as a condition characterized by an “abnormal
enlargement of the airspaces distal to the terminal bronchioles, accompanied by
destruction of their walls and without obvious fibrosis.” COPD is mostly caused by
cigarette smoking. The hereditary form of emphysema is responsible for less than 1 % of
COPD diagnosed in the United States (ATS, 1995, p.78-79).
Alterations in the mechanical structures of the lung, from COPD such as high
dead space leads to an increased mechanical load and compromised muscular efficiency
leading to dyspnea (ATS, 1999, O’Donnell & Webb, 1992). Exertional dyspnea in the
COPD population seems to result from the output of neural motor structures to the
respiratory systems of individuals with COPD (Marin, Oca, Rassulo, & Celli, 1999).
Additionally, there has been growing evidence that skeleton muscle, especially the
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muscles of ambulation, do not function normally in COPD patients contributing to
exercise intolerance (Casaburi, 2000). This deficiency can also contribute to exertional
dyspnea in this population.
The expiratory volume in one second (FEVi) is a measure of airflow obstruction
in COPD patients. This measure, can be also expressed as the percentage of predicted
volume (FEVi % predicted). The FEVi % predicted can be used to quantify the severity
of lung impairment and is easily obtained with spirometry. It has been used in clinical
practice, and has been shown to have less variability than other measures and to be able
to predict accurately for age, sex and height (ATS, 1995).
Normal FEVi values may vary from laboratory to laboratory. This variance is
expected if the laboratory adjusts the reference values to the characteristics of the
population being tested, as recommended by the ATS ( ATS, 1994). Acceptable values
for FEVi % predicted are >85%. The values used as reference at the laboratory at the
institution where this study was carried are individualized based on height and age
(Crapo, Morris & Gardner, 1981).
Patients with COPD can be categorized into three groups based on the severity of
airflow obstruction measured by the FEVi % predicted: Stage I, FEVi> 50% predicted;
Stage II, FEVi35 to 49% predicted; and Stage III, FEVi < 35% predicted (ATS, 1995,
p.83). Patients in Stage I, comprise the majority of patients with COPD, and generally do
not experience severe hypoxemia. Patients in Stages II and III, include the minority of
patients. In these patients, however, the disease has a significant impact on their lives
(ATS, 1995).
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Dyspnea in the COPD population is often explained on the basis of increased
mechanical workload. Increases in workload are caused by pulmonary damage resulting
in ventilation/perfusion mismatch and hypoventilation. Considering dyspnea overtime in
patients with severe lung impairment, studies have found no correlation between dyspnea
and the decline of lung function and no explanation for this phenomena (Eakin, E.,
Kaplan, R., Ries, A. & Sassi-Dambron, D., 1996, Lareau, Meek, Press, Anholm & Roos,
1999).
Some of the treatments available to reduce the mechanical load in this population
and improve function are: exercise training, supplemental oxygen during exercise,
inhaled pharmacological agents, fans, vibration, and lung volume reduction surgery.
Pulmonary rehabilitation, has been shown to reduce dyspnea and increase exercise
tolerance in the COPD population (ATS, 1995; ATS, 1999; O’Donnell, Lam & Webb,
1998, O’Donnell, Bain & Webb, 1997). The role of anxiolitics for the improvement of
dyspnea is still unclear. Studies of anxiolitics_have failed to consistently demonstrate
improvement in dyspnea (ATS, 1999).
Dyspnea in the Congestive Heart Failure Population
Congestive Heart Failure “is a complex syndrome manifested by shortness of
breath, fatigue, and abnormal heart function” (Laurent-Bopp, 2000, p.560). CHF is the
most common cause of hospitalization in acute facilities, especially in the elderly
population (Shah, Der, Ruggerio, Heidenreich & Massie, 1998; Butler et al., 1998).
Physiologic changes causing heart failure are: abnormal volume load, abnormal
pressure load, myocardial dysfunction, filling disorders, and increased metabolic demand.
When the heart is presented with one of these conditions, it starts to use a compensatory
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mechanism that may involve multiple responses and affect other organ systems. Some of
these responses are hemodynamic, renal, hormonal, neural, and cellular. These responses
can contribute to an increased tissue oxygen extraction and decreased delivery leading to
breathing discomfort often reported by CHF patients (Laurent-Bopp, 2000, p.562;
Krumholz et al., 2000).
A common measure utilized to evaluate ventricular function in patients with CHF
is the ventricular ejection fraction or Ejection Fraction( EF) test. The evaluation of
ventricular function is a critical determinant of morbidity, mortality for patients with
cardiac disesase. It is critical in establishing an appropriate plan of care for these patients.
The acceptable normal values for EF are 50% at rest having acceptable normal limits
ranging between 55-75% in adults (NYHA, 1994, p. 284 and 314).
According to the New York Heart Association (NYHA) classification of heart
failure functional capacity has been categorized into 4 classes based on patient’s
functional capacity and evidence of cardiovascular disease (NYHA, 1994, pp.253-256):
1. Class I: In this group are the individuals with cardiovascular disease that
does not cause fatigue, palpitation, dyspnea, or anginal pain when
performing ordinary physical activity.
2. Class II: Individuals have evidence of Cardiovascular disease. They are
comfortable at rest but ordinary activity causes fatigue, palpitation,
dyspnea or anginal pain.
3. Class III: Individuals with cardiac disease causing marked limitation of
activity. Although comfortable at rest, less than ordinary activity cause
fatigue, palpitation, dyspnea, or anginal pain.
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4. Class IV: Individuals with cardiac disease causing increased discomfort
with minimal physical activity or inability to perform physical activity
without discomfort. Fatigue, dyspnea, palpitation, or anginal syndrome
may occur at rest.
This classification is based upon subjective and objective assessments. The
subjective assessment includes the functional capacity of the individual or their ability to
perform physical activity. The objective assessment is based on diagnostics
measurements such as electrocardiograms, stress test, x-ray, echocardiogram, and
radiological images (NYHA,1994, Chizner, 1996).
Of all the symptoms of heart failure, dyspnea and fatigue are among the most
common (Friedman, 1997, Parshall, 1999). Other manifestations of CHF are dizziness,
confusion, pulmonary congestion, hypotension, increased venous pressure, jugular
distention, hepatomegaly, dependent peripheral edema, ascites, and death (Jennings &
Steenbergen, 1998; Laurent-Bopp, 2000, p.560-562; Wilson et al, 1999; Russell,
McNeer, & Higginbotham, 1998).
The mechanisms of dyspnea in heart failure seem to differ from mechanisms in
COPD patients. Studies have found that there are measures that can be useful to
differentiate pulmonary and cardiac causes of dyspnea such as the end-tidal carbon
dioxide (e.g. Brown, Gough, & Seim, 1998), Peak Expiratory Flow (PEF), and oxygen (e.
g. dyspnea differentiation index-DDI) (Ailani et al., 1999, p.l 104). This study found that
PEF and O2 are lower in patients with pulmonary due to the impairment in their large
airway while patients with CFH have their large airway function unaffected.
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Recent work explored some of the mechanisms of dyspnea and suggested that
triggers other than workload elicit dyspnea in heart failure patients. For instance, a study
addressing dyspnea during exercise in patients with heart failure and post heart transplant
patients, found that the sensation of dyspnea was not determined by the work of
breathing, but rather triggered by a lack of perfusion of the respiratory muscles (Mancini,
La Manca, Donchez, Henson, and Levine, 1996). Other changes that may affect breathing
in patients with CHF patients are increased respiratory pressures due to increased minute
ventilation, decreased lung compliance, and increased airway resistance (Al-Rawas et al.,
1995; Evans, Watson, Cowley, Johnston, & Kinnear, 1995)
Other work has shown that the symptoms of exertional dyspnea in heart failure
patients is not determined by ventilatory function although the lungs may be involved.
This study found that FEVi% predicted, ejection fraction, NYHA functional class,
resting hemodynamics tests did not predict the dyspnea patients experienced, at the end
of exercise (Russell et al., 1998, p.401). Additionally, another study has demonstrated
that pulmonary function does not contribute to limitation during exercise in stable CHF
patients (Chauhan et al., 2000)
The treatment for dyspnea in CHF patients comprises of removal of the
precipitating causes, corrective surgery, and medications (Laurent-Bopp, 2000, p. 570).
Cardiac rehabilitation programs have been shown to benefit CHF patients. Patients that
participate in rehabilitation programs have increased life expectancy and reduced
readmissions and emergency room visits. Because of the multiple interventions of cardiac
programs, it is still difficult to identify the exact intervention that brings positive
outcomes (Greenland, 1996; Ades, Pashkow & Nestor, 1997; Hall, 1998).
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In summary, the literature cited previous sections suggests that there are different
mechanism of dyspnea in the COPD and CHF population. This difference may cause
patients with these conditions to perceive dyspnea differently.
Qualitative Aspects of the Dyspnea Symptom
At present, most of the studies on dyspnea have reported on the quantitative
aspects of this symptom by addressing the pathophysiology, diagnostic tests,
measurements, or treatment. Even though there are acceptable theories to explain
dyspnea, some of the mechanisms are still unclear. This section will briefly highlight
some of the qualitative or subjective factors that may influence the patient’s perception of
dyspnea such as emotion and behavior.
Studies have shown emotions affect the patient’s breathing. Emotional arousal
can have positive or negative affects on individuals with pulmonary conditions. The most
common emotions identified in the study by Janson-Bjerklie, Carrieri-Kohlman and
Hudes (1986) were: “being upset, worried, angry, or excited.” Gender differences
between male and female participants were also identified. Emotional triggers seem to
affect females more than males (Janson-Bjerklie et al., 1986). Other study has indicated
that the level of depression in COPD patients influence the degree of dyspnea
experienced (Calhoun, 1989). Another study found that patients with COPD identified
feelings of fear, helplessness, loss of vitality, preoccupation, and legitimacy towards their
breathing. In the study, patients identified some therapeutic behaviors they expected from
their nurses. Patients expected nurses not only to provide treatment for their breathing but
also “acknowledge and believe” in the symptoms they reported (De Vito, 1990).
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Research has shown that COPD patients were able to differentiate emotions (e.g.
anxiety) from their physical symptoms or intensity of their dyspnea (e.g. effort of
breathing) (Carrieri-Kohlman et al., 1996). Although the qualitative factors influencing
the study of dyspnea needs further investigation, respected organizations such as the ATS
have made statement dyspnea as a subjective experience influenced by
pathophysiological, psychosocial, and environmental factors. As a result, the treatment of
dyspnea has multiple approaches including addressing the patients emotions. For
instance, the use of opioids and anxiolytics have been used in patients with dyspnea to
alter mechanisms affecting emotional responses. However, because the benefits of this
therapy are still unclear, indication for the opioids and anxiolytics in the treatment of
dyspnea are controversial (ATS, 1999).
The literature has suggested that the patient’s interpretation of their symptoms
affect their behavior towards the disease. For example, the belief that some symptoms,
such as dyspnea, are a normal consequence of aging is commonly reported in the elderly
population (Silvestre & Mahler, 1993). A study with elderly heart failure patients (mean
age 76 ± 6.9 years), showed that patients experienced symptoms for a relatively long time
before seeking care at an acute care facility. This study found that age, history of disease,
gender, and pattern of presentation of symptom influence were related to the length of
time patients experienced symptoms before their hospital admission (Friedman, 1997, p.
169). Dyspnea was the most common symptom reported by the participants. Nine-two
percent of the patients reported having experienced dyspnea for three days before
admission, 37% acute dyspnea for 12 hours, 35% experienced edema for seven days,
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33% cough for seven days, 30% orthopnea for two days. Other symptoms reported were:
chest pain, fatigue, nausea, palpitations, and weight gain (Friedman, 1997, p. 169).
The meaning patients give to their symptom seems to affect the strategies used to
manage and cope with the symptoms and how they report them. For example, patients
with CHF attempted to manage their dyspnea by lowering their salt intake and increasing
diuretics before they sought care for their symptoms (Friedman, 1997, p. 169). It has been
reported that patients with COPD used adaptative strategies to relieve their breathing
discomfort such as implementing changes in their grooming, reducing mobility and social
activities.
Another qualitative factor that may influence a patient’s perception and report of
dyspnea is culture. Hardie et al. (2000) studied White and African American asthma
patients. They a significant relationship between the patient’s race, symptom appraisal
and language to describe the symptom. Previous studies support this finding that gender
and race influence patient’s perceptions of symptoms such as dyspnea (Janson-Bjerklie,
et al., 1986) Health professionals who understand the impact of multiple factors on
dyspnea, are better prepared to deal with patients that have difficulty expressing their
condition or that perceive their symptoms differently (ATS, 1999, p.321).
This study has a multidimensional approach to dyspnea. Studies have supported
the importance of addressing the qualitative aspects of dyspnea. The terms patients use to
report dyspnea is a critical aspect that needs to be considered when diagnosing and
treating patients with cardiac or pulmonary conditions.
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The Language of Breathlessness
Breathlessness or dyspnea is a common reason for COPD and CHF patients
seeking medical help (Janson-Bjerklie et ah; 1986; Friedman, 1997; Travis et al., 1998;
Parshall, 1999). Dyspnea alone has been associated with “an approximate twofold
increase in the likelihood that COPD and CHF patients were admitted to the emergency
department” (Parshall, 1999, p.62).
The language patients use to communicate their symptoms is important to the
assessment of dyspnea. Studies of dyspnea descriptors, especially in the last decade, have
provided a better understanding of the qualitative aspect of dyspnea and also raised new
questions about the theories on the pathophysiology of dyspnea (Simon et al., 1990;
Elliot et al. 1991; Parshall, 1999; Mahler et al.,1996). These studies have shown that
patients with different pathophysiologic conditions can use different descriptors to
characterize their respiratory discomfort (ATS, 1999).
Although there may be controversy regarding the accuracy of symptom reports,
the language patients use to describe their symptoms, provides important information that
will guide diagnosis and treatment of various disease states (ATS, 1999 p.325) For
example, studies have suggested that patients may adopt the terminology of health
providers, which can bias the language they use to report dyspnea. (Janson-Bjerklie et al.,
1986; Hardie, Janson, Gold, Carrieri-Kohlman & Boushey, 2000).
Another concern about studying patient reports of dyspnea is their ability to
accurately recall dyspnea when there are not experiencing it. There is beginning
evidence that both COPD and CHF patients can accurately recall dyspnea after exercise
(Stulbarg, Carrieri-Kohlman, Gormley, Tsang & Paul, 1999). Studies of patients with
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cardiopulmonary conditions have indicated that patient’s recall of dyspnea at rest, was
reliable and comparable to dyspnea when walking (Mahler et al, 1996). Additional work
has shown that patients are able to recall accurately the worst dyspnea they experienced
after exercise (Stulbarg et ah, 1999). Heart Failure patients were able to reproduce their
experience with dyspnea and fatigue by measurement done with the visual analog scale
(VAS) and Borg scales (Grant et al., 1998). Patients with moderate to severe COPD were
able to recall accurately the intensity of their dyspnea over a period of 2 weeks (Meek,
Lareau, & Anderson, in press). Although there are some limitations to the generalization
of these studies, they suggest patients may be able to accurately report their symptoms
based on their recall of previous experiences.
Many aspects of dyspnea have been explored but few studies have addressed the
difference in the language between COPD and CHF patients. This section will review
work on the language of breathlessness and terms patients with cardiorespiratory
conditions use to describe their breathing. Studies addressing dyspnea in the COPD and
CHF population will also be reviewed.
Early efforts to identify different types of dyspnea were reported in 1965 at an
international symposium on respiratory disease at the University of Manchester, U.K. In
this document six different grades or types of dyspnea were identified: 1) awareness that
there is a little increase in ventilation, 2) a little shortness of breath (harder to get one’s
breath) 3) deep breathing (e.g. an individual who had just run a race), 4) sensation of
hindered breathing, 5) the sensation of suffocation 6) the sensation at the breaking point
of breath holding (Comroe, 1966, p. 235). The consensus at that time, was that there
were no precise term to label each of these sensations.
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Simon et al. (1989), studied breathlessness in normal individuals. This work is the
first that attempted to identify and list descriptors of dyspnea in various respiratory
conditions. A list of 19 descriptors of breathlessness was created based on descriptors that
had been previously identified by patients with cardiopulmonary disease. Normal
subjects identified from this list breathlessness descriptors while exposed to eight
different activities that caused dyspnea. The participants were to select descriptors that
better described their breathing while they were exposed to these activities.
This list of 19 descriptors of breathlessness was studied in a group of 53 patients
with seven different diseases (Simon et al., 1990). Among those studied were 16 patients
with COPD (FEVi% mean : 49 ± 12 % / pred.: 39 ± 16 % ) and five with CHF. They
found that “patients with breathlessness resulting from a variety of pathophysiological
conditions experience qualitatively different sensations” (Simon et. al 1990, p. 1012).
The authors identified different clusters (groups of terms) describing dyspnea, based on
those found in their earlier study with normal subjects. In the COPD group, descriptors
were primarily from the “work” cluster: “my breathing requires effort”, “my breathing
requires more work”. The descriptors that emerged from the CHF population were from
the “rapid” cluster; “I feel my breathing is rapid”, and from the “suffocating cluster”; “I
feel I am smothering”or “I feel I am suffocating”. Both COPD and CHF patients shared
descriptors from the “hunger” cluster: “I feel hunger for more air”, “I feel out of
breath”, or “I cannot get enough air”(Simon et al., 1990, p. 1011-1012).
While this was new information, the number of subjects studied was limited, and
severity of the CHF group was not known. The generalizability of the findings to the
COPD and CHF populations were therefore limited. Inpatients and outpatients where
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included in this study, suggesting information reflected acute as well as chronic
responses. No detailed demographics of this population was given such as education,
gender, socio-economic status or race.
Others have studied the language of breathlessness and used the list of terms
developed by Simon and colleagues (1989), to identify descriptors in different
populations. For example, work by Elliot et al. (1991) attempted to expand this work by
creating a new list of 45 dyspnea descriptors. They used Simons et al. (1989) list of 19
descriptors and added others identified by health care providers.
Elliot et al. (1991) used the list of 45 descriptors to study 169 patients with
cardiopulmonary disease, 39 with COPD and 32 with cardiac disease. Other conditions
included in this study were patients with: asthma (31), restrictive disease (30), and others
(37). Because the cardiac disease group was not identified by types of cardiac conditions,
the number of patients with heart failure versus other cardiac disease could not be
determined was not reported. In this study, most of the COPD patients selected
descriptors that were grouped in this study in the Cluster One: “I feel out of breath”, “I
feel short of breath”, “I feel puffed”, “I feel breathlessness”, “I am aware of my
breathing”, “I feel a need to breathe”, “my breathing takes too much effort”, “it is
difficult to breathe”, “I can’t get enough air into my chest”, “my breathing is not
sufficient”, “my breath does not go in enough”, “I feel I cannot breathe deeply enough”,
“I feel I cannot breath enough”, “I want to take in more air”, “I feel a need to take in
more air”, “I feel a need to take a deeper breath”, “my breathing is too shallow”, and “I
do not feel satisfied by my breathing”.
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The cardiac patients did not select any of the descriptors from Cluster One. Most
of the cardiac population selected the descriptor in Cluster Three: ‘T feel wheezy”. The
COPD population did not select the Cluster Three descriptor (p. 827-828).
Elliot et al. (1991), found that patients with different conditions distinguished
different sensations of breathlessness, agreeing and complementing the work of Simon et
al. (1990). While this study identified descriptors common to different health conditions,
no comparison between COPD and CHF patients was done. The number of patients
studied with CHF was not reported. The study included inpatients and outpatients, with
the majority of the participants males. The mean age of COPD patients and cardiac
patients was the same, 65 years. Additionally, other demographic characteristics such as
race, education and economical status were not reported. Because the instrument utilized
in the study utilized some descriptors generated by healthcare personnel, it is not clear
how closely their terms approximate those patients would use to describe their breathing.
Mahler et al. (1996) replicated Simon’s and colleagues work by studying
breathlessness in patients with eight different conditions. A sample of 218 patients was
recruited from an outpatient pulmonary clinic or pulmonary laboratory, of which, 85 were
COPD and 17 CHF. The COPD patients had severe airflow obstruction (FEVi predicted:
43.3 ± 16.3 %) while CHF patient’s were mildly obstructed to normal (FEVi predicted:
82.8 ± 20.3%). The age of COPD (65.6 ± 8.4) and CHF (66.0 ± 10.4) participants were
similar.
The original list of 19 descriptors by Simon et al. (1990) was reduced to create a
list of 15 descriptors. Results showed that “patients with different cardiorespiratory
conditions experience distinct qualities of breathlessness”(Mahler et al., 1996, p 1357).

30

The authors identified clusters of descriptors that were more common to COPD than CHF
patients. The descriptors selected by COPD patients were from the work/effort cluster:
“my breathing requires effort” (51%), “I feel out of breath” (49%), I cannot get enough
air in”(38%). The descriptors selected by CHF patients were under three clusters 1)
work/effort: “my breathing requires effort (47%), “I feel out of breath” (35%); 2) tight:
“my chest feels tight”; and 3) inhalation/exhalation clusters: “my breath does not go in all
the way” (29%), “my breath does not go out all the way” (29%) (p. 1360).
Recent work described dyspnea by patients with cardiopulmonary disease in the
emergency department (ED). In a study of 986 patients presenting to the emergency
room, COPD (n = 239) and CHF (n = 320), dyspnea was reported by most patients with
COPD (78.2%) and CHF (61.6%) and was the primary reason patients sought care.. The
terms patients used to report dyspnea, were identified and coded according to the
National Center for Health Statistics (NCHS) reason for visit classification (Parshall,
1999, p.63). The most common complaints of COPD patients regarding their breathing
were first “shortness of breath” (50.2%), second “labored/difficult”(19.8%), and third “
cough” (13.4%). The CHF patient’s most common complaint was “ shortness of breath”
(47.8%), second “ chest pain”(20.6%), and third “labored/difficult” breathing (13.1%).
Shortness of breath and labored and difficult breathing were present in both COPD and
CHF population. Breathing that required “work” and “effort” which probably could be
reflected in the terms as “labored/difficult breathing”, was found in work by Mahler et al.
(1996) in COPD ( 51%) and CHF( 47% ) patients. In work by Simon et al. (1990)
“effort” or “work” were descriptors that were common only to the COPD. Simon’s study,
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however, only included five patients with CHF and 16 with COPD, While Mahler studied
17 patients with CHF and 85 with COPD .
Related Studies
Janson-Bjerklie et al. (1986) studied the recall of dyspnea sensations during acute
episodes of dyspnea in a group of 68 pulmonary patients in which 27 with COPD, 23
with asthma, 12 with restrictive disease, and 5 with vascular disease. Their aim was to
study the coping strategies used by patients with different pulmonary diseases. They also
identified intensity of dyspnea in the various groups.
The sensations that were common to the COPD group comprised by inpatients
and outpatients participants were: “Shortness of breath”, “Hard to breath”, “Feel like
need air”. The percentage patients used these descriptors was not reported. Most of
participants (66 of 68) selected “Shortness of breath” as the most frequent phrase to
describe dyspnea (Janson-Bjerklie et al., 1986, p.158). While Parshall (1999), reported
40% of the participants identified “Shortness of breath” as a descriptor (394 of 986). In
addition to the descriptors, the intensity of dyspnea reported in the COPD group varied
from 35.6 (SD = 17.8 ), usual mean score, to 72.0 (SD = 19.9 ) worst mean score on the
Dyspnea Visual Analog Scale ranging from 0 (no breathless at all) to 100 extremely
breathless). Dyspnea was “more or less” constant in this group ( Janson-Bjerklie et al.,
1986).
A study utilizing the PFSDQ identified intensity in COPD patients enrolled to a
pulmonary rehabilitation program. These individual that had mild, moderate, or severe
airway obstruction reported moderate level of dyspnea on most days (M = 5.6, SD = 2.0)
and in most day-to-day activities (M = 5.8 = SD = 2.0) in a scale that ranging from 0 (no
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shortness of breath) to 10 (very severe shortness of breath) (Lareau, et ah, 1994).
Another study, including advanced COPD enrolled in an outpatient rehabilitation
program, identified a wide range of dyspnea intensity. Intensity varied from severe
breathless (M = 2.5, SD = 1.5) to mildly breathless (M = 8.5 , SD = 1.5) in the baseline
dyspnea index (BDI) ranging from “O” very severe breathless to “12” unimpaired
(O’Donnel and Webb, 1992).
There were two studies that identified dyspnea intensity in the COPD and CHF
population. In a study including inpatients and outpatients (CHF = 5, COPD = 16),
found that both groups experienced moderate to moderately severe ( 5-8 in a 0-10 scale)
on the Borg Scale. No difference in dyspnea intensity between the groups are reported
(Simon et al., 1990). The other study including outpatients with CHF (n = 17) and COPD
(n = 85 ), found that the mean dyspnea intensity reported in the CHF group was higher
(M = 5.7, SD = 2.6) than the mean of dyspnea reported COPD (M = 4.3, SD = 2.1) on
the BDI The significance of the difference between groups was not reported (Mahler et
al, 1996).
Skevington, Pilaar, Routh & Macleod (1997) identified 63 descriptors of
breathlessness in patients with respiratory, oncology or cardiac diagnoses. The 63
descriptors were analyzed by content and sorted in classes according to the judgment of
experts (not patients) by their frequency and severity. They were then reduced to 35
descriptors. Four groups emerged from their list descriptors: physical sensations,
affective or evaluative, low energy, and hyperventilation. The physical and affective
descriptors of the dyspnea symptom identified in this study, also found in previous
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studies were: the sensation of puffing, wheezy, breathless, fighting for air, pressure,
airless, fear hopeless, and exhaustion.
Skevington et al. (1997) found that most of the patients selected descriptors
expressing the physical component of dyspnea. The second descriptors selected were
those included in the affective and evaluative class. It was suggested that the physical
component was the most important feature even though the “affective or evaluative”
components were present (Skevington et al., 1997). Dyspnea descriptors identified in
this work are consistent with previous findings. Because the study did not associate the
descriptors with health conditions, it presents a limitation for the understanding the
specific terms COPD and CHF use to describe their breathing.
Recently, breathlessness descriptors used by African American and Caucasian
asthmatic, were studied (Hardie et al., 2000). Their findings suggested there is a
significant relationship between the patient’s race, with symptom appraisal and language
used to describe the symptom. African American patients used different terms to describe
their sensations from those terms used by Caucasians. Even though this study was limited
to asthma patients, it suggests that ethnographic characteristics are an important aspect
and should be considered when evaluating symptoms.
Summary
Patients with respiratory and cardiovascular diseases account for approximately
two-thirds of all cases of dyspnea (Mahler et al. 1996, p. 1357). Although the frequency
and severity of dyspnea in the COPD and CHF populations has not been clearly
described, dyspnea is a common symptom among this population (Parshall, 1999,
Friedman, 1997, p. 169). Studies to date, have not looked at differences in stable COPD
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and CHF patients with severe impairment. Furthermore the sample size of the studies that
have included COPD and CHF patients were small with fewer than 20 participants in one
or both group (Simon et ah, 1990, Elliot, 1991, Mahler et ah, 1996). Only one study on
dyspnea has included a large number of COPD and CHF patients, however retrospective
data of acute patients were used, and dyspnea descriptors was not a specific aim of the
study (Parshall,1999).
It has been demonstrated that patients with different health conditions appear to
use unique terms to describe their dyspnea but it is not known which terms may be
unique to COPD and CHF patients. This study attempts to fill this gap by providing better
understanding of the terms used by this population. In addition, this study aims to provide
further knowledge on the frequency and severity of dyspnea in the COPD and CHF
population.
Mahler and Harver (2000) has suggested that because “language is a symbolic
form of communication that enables sharing ideas, thoughts, and in-the medical settingsymptoms”, it is critical that health care providers are able to elicit accurate information,
in order to optimize care (p.928).
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MATERIALS AND METHODS
Design
The purpose of this cross-sectional, descriptive study was to investigate the most
common descriptors of dyspnea or breathlessness used by stable patients with COPD and
CHE. It also aimed to identify the frequency and the severity of dyspnea in these
populations. The breathing discomfort of the participants was addressed in several ways:
(a) identification of the common terms both populations use to describe their breathing,
(b) similarities and differences of the terms identified with those reported in the literature,
and (c) identification of frequency and severity of dyspnea.
Demographic variables included race, socioeconomic status, level of education,
marital status, current use of medication, oxygen delivery, smoking history, comorbid
conditions, severity of the disease, EF and FEV i values.
Setting
Approval was obtained by the Human Subjects Subcommittee of the Jerry L.
Pettis Veterans Medical Center (JLPVAMC) in Loma Linda, CA where participants were
recruited from the Pulmonary and CHF outpatient Clinics. The Pulmonary and CHF
Clinics each see on average 40-50 patients each week. Patients seen in these clinics are
usually stable. The Pulmonary clinic provides diagnostic, therapeutic, and ongoing
management of COPD and patients with other lung conditions. The CHF clinic provides
comprehensive care for patients with CHF.
Sample
The total population receiving care at the facility where the sample was
withdrawn was comprised of 32030 males and 3808 females veterans. The maleifemale
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ratio is 8:1. From the male population, there were 15,343 Caucasians, 2240 Blacks, 2122
Hispanics, 168 Asian or Pacific Islanders, 59 American Indian or Alaska Native enrolled
in that facility. A total of 12098 had not their ethnicity recorded/reported. Among the
patients that have reported their ethnicity 77% were Caucasians, 11% African-American,
10.7 Hispanics, .8% Asians and Pacific Islanders, and .3% American Indian or Alaska
Native (JPVAMC, 2001).
The purposive sample consisted of: 30 COPD patients and 30 CHF patients with
the clinical diagnosis of moderate to severe COPD or CHF. The first 30 participants, in
each group, that met the criteria and agreed to participate were included in the study. A
non-random purposive sample was collected from March 15th to June 28th of 2001. The
inclusion and exclusion criteria for participants in this study were:

Exclusion Criteria
• Hospitalized in the last 4 weeks

Inclusion Criteria
• Stable patients with diagnosis of
COPD or CHF for at least one year.
•

COPD patients in stage II and III

• CHF patients with functional capacity

• Mental Impairment

class III, and IV.
• Age 18 or older
• Visual or hearing deficit that would

• Able to read, speak, and understand

interfere with participation

English
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Power Analysis
Power analysis indicated that eighteen participants were needed for a power of .80
and a= .05 (Borenstein and Cohen, 1988). The mean score used as a basis for the
calculation was the dyspnea severity rated by COPD patients on “most days” based on
the zero to 10 rating of the PFSDQ (Lareau et al., 1994). For determining this mean the
scores used were: (a) population 1, patients with COPD (M = 5.6, SD = 1.4) and
population 2, patients with CHF (M = 3.7, SD = 1.4). The standard deviation used in this
power analysis was more strict than the original study (SD = 2.0) (Lareau et al., 1994).
Because no studies have applied this instrument in a CHF population, this calculation was
made on the assumption that dyspnea intensity could be greater in the COPD patients due
to a greater degree of hypoxia they experience than CHF patients (Ailani et al., 1999,
p. 1104). Lareau et al. (1994) found that there is a minimal difference of 1.9 between
means that need to exist in order for this difference to be significant. For this reason this
value (1.9) was subtracted from the population 1 (M = 5.6) in order to determine a mean
to population number 2 (M = 3.7) for the calculation of the power analysis.
Polit and Hungler (1999) suggested that there are many factors to consider when
determining the sample size for qualitative studies. They stated that “In general, the
greater the number of independent and extraneous variables, the larger the sample should
be. In a study where research design can be laid out such that the number of ‘cells’ can be
determined, then the study should aim to have at least 20 to 30 subjects for each cell of
the design” (p.292). Additionally by using the highest suggested number and equal
number of participants with COPD and CHF, this study aimed to fill a gap on the
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understanding of descriptors, frequency, and intensity of dyspnea in the COPD and CHF
population.
Data Collection Procedures.
Individuals scheduled to be seen in the Pulmonary or CHF clinics were
considered for the study. Records of subjects, such as FEVj and EF were reviewed for
eligibility. Most of the patients were interviewed after seeing the clinician. The subjects
were then approached, described the study, and asked to participate. If the patient agreed
to participate, they were provided with verbal and written explanations about the study
and received the informed consent to read (Appendix E). Following agreement to
participate, subjects were asked to sign the consent form. A copy of the signed consent
was mailed to each subject, a copy stored in the patient’s file, and a third copy retained
by the JLPVAMC principal investigator.
The sequence of the data collection after the signing of the consent forms
consisted of the following:
1) Completion of the demographic information (Appendix F) questionnaire by
the patient with the supervision of /coaching of the investigator.
2) Open-ended question about breathing was asked (Appendix B, question 1):
“Which words would you use to describe your breathing when it is
uncomfortable?” The exact words of the patients were written on the form.
3) Instruction of how to fill the questionnaire (Appendix C) were read aloud for
the participants: “ Put a number next to the phrases that best describe your
breathing. If you choose more than one phrase to describe your breathing
please write the numbers “1”, “2”, and “3” near the phrase. For example,
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place number 1 near the phrase that best describes your sensation, number 2
for the second best, and number 3 for the third best descriptor. If only one or
two phrases seem appropriate, you should only select those one or two phrases
(in other words, you do not have to pick three phrases).” The list of
descriptors (Appendix C) were offered and the subjects were asked the two
questions (Appendix B): “Please choose from this list the top three phrases
that best describe your breathing.” and Are there any other phrases you would
like to add to the phrase(s) you have chosen?”
4) General dyspnea questionnaire from PFSDQ (Appendix A) was administered.
Opportunity for clarification was offered if needed.
The total time for the data collection was of approximately 15 minutes. After each
day of collection, data were locked and carefully stored accessible only by the study
personnel. After the completion of data collection, information was entered in a computer
database. Later it was entered and analyzed by a statistician under supervision of the
investigator. Privacy of the patient was maintained by coding subject identification.
COPD subjects were assigned consecutive numbers beginning with 100, and CHF
subjects were coded beginning with the number 200.
Analysis
This research study utilized an a = .05 to determine significance. Descriptive
statistics, independent two-tailed t-test, and Chi-Square were the statistical test to analyze
the data: (1) descriptive statistics, independent two-tailed t-tests, and Chi Square were
used for the demographic data, (2) descriptive statistics was used for the terms
volunteered by the subjects to describe their breathing discomfort, (3) descriptive
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statistics and Chi Square tests were used for the terms endorsed from the list of
descriptors (Appendix C), (4) descriptive statistics and Chi Square were used to identify
dyspnea and suffocation experience among COPD and CHF (5) descriptive statistics and
independent two-tailed
t- tests were used to identify the frequency of dyspnea among the groups (6) independent
two-tailed t-test were used to identify frequency of dyspnea in the COPD and CHF
populations (6) descriptive statistics, independent two-tailed t-test, and Chi-Square were
used to identify intensity of dyspnea in the COPD and CHF populations. Computer
program SPSS was utilized for data analysis ( SPSS, 2000).
Instrumentation
The instruments used in the present study were: 1) demographic data (Appendix
F); 2) interview questionnaire (Appendix B); 3) list of descriptors (Appendix C) and 4)
the dyspnea general dyspnea questionnaire of the PFSDQ (Appendix A).
Demographic data
The purpose of the demographic data (Appendix F) was to provide descriptive
information that may influence the subject’s response such as: (a) age, (b) sex, (c)
ethnicity (d) diagnosis and (e) length of time patient has been diagnosed, (f) current
medication intake, and (g) severity of the disease. It took approximately two minutes to
compete the information of this questionnaire. For COPD patients, the severity of disease
was established according to the ATS severity classification of COPD; stage I, II, or III
based on the individual’s pre-bronchodilator FEVi values. Thus subjects were classified
as follows (FEVi % predicted): Stage I, FEVi> 50% predicted; Stage II, FEVi35 to 49%
predicted.; and Stage III, FEY] < 35% predicted (ATS, 1995, p.83). For the CHF
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population, the classification of severity was based on the New York Heart Association
(NYHA) classification, CHF: I, II, III, and IV. CHF patients were included in the study if
they were in Class Functional II or greater, in which patients have some breathing
limitations and evidence of cardiac disease.
Interview Questionnaire
The interview was comprised of three open-ended questions: 1) Which words
would you use to describe your breathing when it is uncomfortable? 2) Please choose
from this list the top three phrases that best describe your breathing. 3) Are there any
other phrases from this list, that you would like to add to the phrases you have chosen?
The investigator wrote the subject’s answers for each question using their exact words.
It took approximately 3-5 minutes to complete these questions.
List of Descriptors
Fifteen breathlessness descriptors are listed in this instrument (Appendix C). This
list was developed by applying the original 19-item questionnaire (Simon et ah, 1989) in a
population of 53 patients with seven different conditions including patients with COPD
and CHF. The investigators used 5 different versions of the original questionnaires that
had the same 19 descriptors but listed in different order. The patients selected the best
three descriptors from the list. After the data was analyzed four descriptors from the
original questionnaire were deleted because they were not chosen frequently (Simon et al.
1990, p.1013).
Patients were asked to choose the descriptors that best described their breathing
discomfort. While no measurable validity of this questionnaire has been reported, other
researchers had similar results with its use (e.g. Elliot et al., 1991; Mahler et ah, 1996).
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Theses studies have shown that there is a difference in the terms subjects use to describe
their breathing depending on their health conditions. Approximate time for identifying
those descriptors was 3 minutes.
Pulmonary Functional Status and Dyspnea Questionnaire (PFSDO)
The PFSDQ (Appendix A), provides information on frequency and intensity of
the dyspnea symptom as well as dyspnea associated with 79 activities (Lareau et al,
1994). The PFSDQ is a 164-item, self-administered paper-pencil questionnaire that
requires 15 minutes for completion. This questionnaire was tested and validated on a
population of 131 male patients with severe COPD (Lareau et al, 1994). In this study a
section of the dyspnea component was used. This section consists of six brief general
questions about the dyspnea (Appendix A). Approximate time for the completion of these
questions was 1-2 minutes.
The Questionnaire may be divided in two parts; the first part is the section used in
this study and include questions addressing occurrence of the symptom, frequency, and
severity of dyspnea. The second part assesses dyspnea with daily activities such as body
care, eating, home management, and recreational or social activities.
The first two questions (Appendix A) are yes or no questions, where the
participant marks either yes or no to the questions: (1) Do you ever experience shortness
of breath? (2) Have you ever experienced such severe shortness of breath that you
thought you would suffocate? The third question evaluates frequency: (3) How many
times a month do you experience severe to very severe shortness of breath? Questions
from 4-6 assesses dyspnea in three different periods of time: (4) “on most days during the
past year”, (5) “today” (at the day of the interview), and (5) during most day-to-day
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activities. Patients rate, using a 0-10 scale, their recalled dyspnea experience and their
actual dyspnea intensity at the day of the interview. The severity of their dyspnea is
represented by numbers that follows: 0 (none), mild (1-3), moderate (4-6), and severe (79), and 10 (very severe).
The PFSDQ has been recommended for studies that require more detailed
information about activity levels of patients and dyspnea with activities (Lareau, Breslin
& Meek, 1996). Even though this questionnaire has been administered to pulmonary
populations, the statements in the questionnaire likely apply to subjects with CHF when
the focus is on the common symptom of dyspnea.
The PFSDQ has demonstrated strong reliability estimates (Cronbach’s alpha, a)
of each subscale within each component, ranging from a = 0.88 to 0.94. Correlation
between activivies and FEV1 % predicted were significant at p<0.001 level (Lareau et
al., 1994). Beginning construct validity has been demonstrated by comparing the ability
of the participants to perform activities and their pulmonary function the groups with the
most difficulty performing activities and most dyspnea had significantly (p<0.001)
worse pulmonary function.
Human Rights
This study conforms to the Human Studies requirements of both Loma Linda
University Medical Center (LLUMC), Loma Linda, CA and the JLPVAMC, Loma
Linda, CA. All potential candidates received explanation concerning the study. The
individuals who agreed to participate were provided enough time to read the consent
form and to ask questions. The consent form for the JLPVAMC, where recruitment took
place, is in Appendix E.
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There was no risk involved in this study to the subject. Subjects were informed
that they could withdraw from the study at any time without affecting their care.
Provision was made for subjects to receive information and contact the investigator
during working and after hours if they had any questions or concerns related to the study.
Participants were informed about their rights and received a copy of the consent form.
Confidentiality was maintained by protecting the identity of the participants and by
locked storage of the data collected.
Summary
This study aimed to provide a better understanding of dyspnea in the COPD and
CHF populations. This study had a non-experimental and cross-sectional design. The
sample was comprised of 60 patients: 30 patients with COPD and 30 with CHF for a
power of .80 and a = .05. The data were collected at the outpatient Pulmonary and CHF
clinics at the JLPVAMC. The participation in this study was voluntary. Patients that
agreed to participate received further explanation about the study and signed a consent
form. Data collection for each subject occurred at one session with the subjects answering
one open-ended question, selecting three descriptors of breathlessness, and completion of
a 6-item paper and pencil questionnaire. The total amount of time to collect the data was
approximately 15 minutes. Descriptive statistics and Chi-Square test was used to identify
the most common terms used to describe breathing discomfort. Descriptive statistics,
Chi-Square, and independent two-tailed t-tests were used to characterize dyspnea and
suffocation experience including times a month the participants experienced severe to
very severe dyspnea. Descriptive statistics, and independent two-tailed t-test were used to
identify the intensity of dyspnea in the COPD and CHF groups.
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RESULTS
This study addressed breathlessness in patients with COPD and CHF by (a)
characterizing the most common terms used to describe their breathing, (b) identifying
the frequency of dyspnea and (c) determining the severity of dyspnea in patients with
COPD and CHF.
This chapter presents the findings pertinent to the following research questions: 1)
What are the most common terms COPD patients use to describe their breathing
discomfort? 2) What are the most common terms CHF patients use to describe their
breathing discomfort? 3) Is there a difference in the terms COPD and CHF patients use to
describe their breathing discomfort? 4) What is the frequency of dyspnea in COPD
patients? 5) What is the frequency of dyspnea in CHF patients? 6) What is the intensity of
dyspnea in patients with COPD? 7) What is the intensity of dyspnea in patients with
CHF? Additionally, other findings of this study will be reported.
Sample Characteristics
Tables 1, 2, and 3 present the demographic characteristics of the participants. A
total of 73 participants were approached (COPD = 37, CHF = 36), 60 participants met the
inclusion criteria. Six of the patients interviewed in the CHF group were excluded for
being: (a) hospitalized the week prior to the interview (n_= 1), (b) severely impaired on
spirometry FEVi < 50% (n_= 3), (c) classified as functional class I (n = 1), and (d)
diagnosis of CHF less than a year (n = 1). Seven patients were excluded in the COPD
group for being: (a) Stage I (n_= 5), (b) hospitalized in the last month (n_= 1), and (c)
diagnosed with COPD in less than a year (n = 1).
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Sixty male patients were enrolled in the study, 30 with COPD and 30 with CHF.
The COPD group was significantly older (M = 67.97) than the CHF group (M = 61.10)
t = 2.674 (p = .010 ). Subjects with COPD ranged in age from 49 to 83 years while the
CHF group ranged from 41 to 86 years.
Overall the study sample consisted of 50 Caucasian subjects (83.3%), 7 AfricanAmerican (11.7%), two Hispanics (6.7%), and one of Philipino/German ancestry (3.3%).
The COPD and CHF groups were each comprised of predominantly Caucasians (93.3%
and 73.3% respectively). There was a significant difference between the groups in
ethnicity (x 2 = 9.706, p = .008) with the CHF group having a greater number of
Caucasians subjects while CHF included 8 subjects that were not Caucasians (Table 1).
There was no difference in the educational level between the COPD and CHF
subjects (x 2 = 5.232, p = .514). Eighty eight percent of the participants received high
school education or higher (Table 2). Four patients had completed 9th - 11th grade, and
two completed less than 8th grade. The percentage of COPD receiving a high school
education or higher was 83.3% and CHF was 93.4%. One CHF participant did not report
his educational level.
All but two subjects reported their marital status (Table 1). The distribution of
marital status was similar between the COPD and CHF groups (x2 = 1.316, p = .725).
Most were married (51.7%), while 25% were divorced, 13.3% single, and 8.3% widower.
Subjects were categorized by stage of disease (Table 2). Half of COPD
participants were within stage II (FEV) 35% to 49% predicted) and half stage III (FEY)
<35% predicted). Overall, the COPD subjects (n = 30) were severely impaired with an
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Table 1
Socio-demographic Characteristics of 30 subjects with COPD and 30 with CHF
COPD (N = 30)
n (%)

CHF (N = 30)
n (%)

Sex (male)

30(100)

30(100)

Age

30(100)
1 (3.3)
1 (3.3)
20 (66.7)
7 (23.3)
1 (3.3)

29 (96.7)
5(16.7)
11 (36.7)
4(13.3)
7 (23.3)
2 (6.7)

40-49
50-59
60-69
70-79
80-highest
Ethnicity
African-American
Caucasian
Hispanic
Philipino/German
Education
8th grade or less
9-11th grade
High school
Vocational Training
Some College
College
Grad. Work
Marital Status
Single
Married
Divorced
Widow

Significance
X

E

9.706

.008

5.232

.514

1.316

.725

7 (23.3)
22 (73.3)

28 (93.3)
2 (6.7)

1 (3.3)

2 (6.7)
3 (10.0)
10(33.3)
1 (3.3)
11 (36.7)
2 (6.7)
1 (3.3)

1 (3.3)
11 (36.7)
3 (10.0)
11 (36.7)
3 (10.0)

3 (10.0)
15 (50.0)
9 (30.0)
3(10.0)

5 (16.7)
16(53.3)
6 (20.0)
2 (6.7)
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Table 2
Characteristics of 30 Subjects with COPD and 30 with CHF
Characteristics

COPD
n (%)

CHF
SD n(%)

M

Age yrs

30

67.97

6.84

FEV! (L)
FEVi (% predicted)
EF (%)

30
30

1.07
31.67
65.00

.32

1

29
9
9
28

9.76

M

SD

Sig. Tests
t

61.10 10.54 2.674
2.65
.75 -9.165
73.89 19.86 -8.783
26.93 9.51

P
.010
<.001
<.001

COPD Stage (%)
II
III

15
15

CHF Class
(NYHA)(%)
II
III

IV
* Smoking history
Non-smoker
Former smoker
Current smoker
** Pack/years

.976

25 (83.3)
4 (13.3)
1 (3.3)
5 (16.7)
19(63.3)
5(16.7)
24
50.87

29 (96.7)
29

59.97

.334

38.09

30.43

Note. Abbreviations: Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart
Failure (CHF), and New York Heart Association (NYHA), Forced Expiratory Volume
(FEVi), Ejection Fraction (EF)
Normal values: FEVi (L)= individualized FEVio/o predicted = > 85% Normal values
varied according to height and weight according reference used: Crapo et al. (1981).
EF = 55 -75% (NYHA, 1994, pp. 284).
* Significantly difference in smoking history, (x2 =12.083, p< .002).
**Range of pack/year smoked COPD = 3-138 and CHF = 16-150.
p_= < 05
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FEV! 1.07 L (SD = .32) and FEVi of 31.67 % predicted (SD = 9.76) Nine subjects
with CHF had FEVj values available with a mean FEVi of 2.5 L (SD = .75), 73.89%
predicted (SD = 19.86) representing mild airway impairment. The COPD subjects (n
30) had significantly (t = -8.783, p = < .001) greater lung impairment than CHF subjects
(CHF = 9) although the number of subjects in the groups were limited in the CHF group.
Most CHF patients were class II (83.3%, n

25) followed by class III (13.3%, n =

4), and class IV ( 3.3% n = 1 ) based on the NYHA. COPD patients did not have signs of
cardiac disease and therefore were not assigned a NYHA class by their provider. One
patient with COPD had ejection fraction value of 65% (Table 2).
The smoking history of the groups were 83.3% overall with 96.7 % of the COPD
and 80 % of the CHF reporting a history of smoking (Table 2). One subject in each group
did not indicate their smoking history. There was a significant difference on the smoking
history between COPD and CHF subjects (x2 = 12.083, p < .002). All patients with
COPD were former smokers while 5 CHF patients were current smokers, and 5 had never
smoked. For the COPD participants the range for pack years was 3 tol38 and for the
CHF group, 16-150 pack/years. There was no significant difference between pack/years
smoked between groups (t = .976, p = .334).
Four comorbid conditions were significantly different (Chi-Square) between
groups (Table 3). The CHF group had a greater number of subjects with the following
conditions: (a) angina (p = .05), (b) prior myocardial infarction (p < .001), (c) prior
vascularization (p < .001), and (d) dyslipidemia (p = .016). In the COPD group the most
common (i.e., > 40% of subjects) were: arthritis (66.7), hypertension (46.7%), and

50

Table 3
Comorbid Conditions of the Sample
COPD (n = 30)
Conditions

CHF (n = 30)
n(%)

Significant Tests
2

Angina

7(23.3)

13 (43.3)

X
3.842

Prior MI

4 ( 13.3 )

16(53.3)

13.160

<.001

Prior Coronary Vascularization

2

14(46.7)

14.370

<.001

jL(%)

(6.7)

.050

2 (6.7)

2.393

.122

14(46.7)

18 (60.0)

.888

.346

Diabetes

6 (20.0)

12(40.0)

2.594

.107

Peripheral Vascular Disease

4(13.3)

6 (20.0)

.901

.342

20 (66.7)

18(60.0)

.136

.712

Dyslipidemia

12(40.0)

20 (66.7)

5.784

.016

GI disease

3 (10.0)

3 (10.0)

.009

.926

Cancer

3 (10.0)

6 (20.0)

1.191

.275

Valvular Disease
Hypertension

Arthritis

Note.

< 05
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dyslipidemia (40.0%). Among the CHF group, the most common conditions (i.e., > 40%
of subjects) were: arthritis (66.7%), prior miocardial infarction (53.3%), , prior coronary
vascularization (46.7%), hypertension (46.7%), angina (43.3%), diabetes (40.0%), and
dyslipidemia (40.0%).
Table 4 outlines medication and oxygen use in the COPD and CHF populations.
The most common pulmonary and cardiac medicines are listed according to their
category. In the COPD group the most common (i.e., > 60% of subjects) medications
were inhalers: (a) beta-agonists: albuterol (63.3%) and serevent (60%), (b) ipratroprium
(70.0%), and 66.7% on steroids inhalers. Less than 20% of the COPD subjects were on
oral beta-agonists (20%) and oral steroids (10%). Antibiotics were being used by (20%)
of the COPD participants. Additionally under the “Cardiac medications”, < 10% of the
COPD subjects were on calcium channel blockers, ACE inhibitors, beta-Blockers and
diuretics.In the CHF group the most common medications (i.e., > 50% of subjects) were:
(a) ACE inhibitors (56.6%), (b) B- Blockers (90%), and Diuretics (93.3%). Only two
participants were on inhalers, none were on oral beta-agonists, steroids or antibiotics.
Oxygen use was reported by half of the patients with COPD (Table 4) but no CHF
patients reported being on oxygen. Six subjects used oxygen while exercising, 5 used
oxygen continuously, and 4 used oxygen at night time only.
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Table 4
Medications and Oxygen Use

Medications

COPD (n = 30)
£(%)

CHF (n = 30)
n(%)

Pulmonary medicines
B -Agonists Inhaled
Albuterol
Alupent
Serevent
Oral B-Agonist
Ipratroprium
Theophiline
Steroids Inhaled
Oral Steroids
Antibiotics
Cardiac medicines

19(63.3)
2 (6.7)
18 (60.0)
6 (20.0)
21 (70.0)
9 (30.0)
20 (66.7)

1 (3.3)

3 (10.0)
6 (20.0)

1 (3.3)

4(13.3)

ACE Inhibitors

10(33.3)

17(56.7)

Beta Blockers

3 (10.0)

27 (90.0)

Diuretics

3 (10.0)

28 (93.3)

Calcium Channel Blockers

Oxygen use
Continuous
Night only
Exercise

15 (50.0)
5 (16.7)
4(13.3)
6 (20.0)
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Findings Pertaining to the Research Questions
This section reports the results in response to the research questions. The data
obtained by the first open-ended question of interview questionnaire (Appendix B) and a
list of descriptors (Appendix C) responds to the first three questions by identifying the
terms patients with COPD and CHF use to describe their breathing discomfort. Data
obtained from the PFSDQ was used to identify the frequency and the intensity of dyspnea
in patients with COPD and CHF.
Question 1: What are the most common terms COPD patients use to describe their
breathing discomfort?
Patients with COPD and CHF used different terms to describe their breathing
experience. Table 5 outlines the frequency and percentage of subjects reporting the most
common terms participants used to describe their breathing. These terms were
volunteered by subjects in response to the question “What words would you use to
describe your breathing when it is uncomfortable?” (Appendix B). Descriptors are ranked
in order of their frequency and reported as number 1, 2, and 3 descriptors (Table 6). The
most frequent descriptor for the COPD group was: “Scary”(n = 5, 16.7%) and “hard to
breath” (n = 5, 16.7%). The second most frequent (number 2) descriptors were “shortness
of breath” (n = 4, 13.3%) and “cannot get enough air” (n = 4, 13.3%). Third most
frequent descriptors were: “gasping”(n = 3, 10%), “difficult breathing” (n = 3,10%), and
wheezing (n = 3, 10%). Seven terms were volunteered twice in the COPD group (Table
6). The terms volunteered once by this group are not included on Table 6. These terms
are: “ disappointing” , “nervous” , “painful”, “I need to catch my breath”, “severe, “ very
poor”, “it is bad”, “ fast breathing”, I have to stop and rest”.
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Table 5
Dyspnea Descriptors Volunteered by COPD and CHF Subjects

CHF

COPD

Dyspnea Descriptors

n(%)
5(16.6)

n (%)

Scary
Hard to breath

5 (16.6)

3(10.0)

Shortness of breath

4(13.3)

9 (30.0)

I cannot get enough air /oxygen

4(13.3)

4(13.3)

Gasping

3(10.0)

6 (20.0)

Difficult breathing

3(10.0)

3 (10.0)

Wheezing

3 (10.0)

3 (3.3)

Choky

2 (6.7)

Tightness

2 (6.7)

3 (10.0)

Out of breath

2 (6.7)

1 (3.3)

Panicky

2 (6.7)

1 (3.3)

Uncomfortable

2 (6.7)

Exhausting

2 (6.7)

1 (3.3)

Shallow

2 (6.7)

2 (6.7)

Note. Descriptors selected by one subject are reported in the text
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Table 6
Most Frequent Descriptors Volunteered by COPD and CHF Subjects

Descriptors
Ranking
Number 1

Number 2

n(%)

CHF (n = 29)
Descriptor

n(%)

Scary

5 (16.7)

Shortness of breath

9 (30.0)

Hard to breath

5(16.7)

Shortness of breath

4(13.3)

Gasping

6 (20.0)

Cannot get enough air

4(13.3)

COPD (n = 30)
Descriptor

Cannot get enough air 4(13.3)
Number 3

Gasping

3 (10.0)

Difficult breathing

3 (10.0)

Wheezing

3 (10.0)

Note. Descriptors are reported with exact words used by subjects.
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The responses to the list of descriptors (Appendix C) are presented in Tables 7
and 8. The analysis demonstrated that only one phrase from this list was significantly
different between groups characterizing the breathing experience of the COPD group: the
phrase “ My breath does not go out all the way” was selected 11 times by the COPD and
4 times by the CHF subjects (x 2

4.356, p = .037). The most common phrases selected

by the COPD group from this list are reported in Table according their frequency: “I feel
out of breath” (n = 20, 66.7%), “I cannot get enough air” (n = 14, 46.6%), “I fell I am
suffocating” (n = 13, 43.3%), “I feel a hunger for more air” (n ^ 12, 40.0%).
Question 2: What are the most common terms CHF patients use to describe their
breathing discomfort?
For the CHF group the descriptors volunteered in response to the first question of
Appendix B were listed in order of their frequency and reported as number l(most
frequent), 2 (second most frequent), and 3 (third most frequent) descriptors. The most
commonly used descriptor was “Shortness of breath” (n_= 9, 30%), the second
“Gasping”(n = 6, 20.0%), and the third “Cannot get enough air” (n_= 4, 13.3). Terms
volunteered twice are reported in Table 6. Terms volunteered once in this group were:
It hurts”, “Fast breathing”, “Over exerted”, “I cannot breathe”, “Forced breathing”, “It
sounds bubbling”, “Drowning Sensation”, “I feel dizzy”, “I feel light headed”, “
Panting”, and “Winded”.
From the list of descriptors (Appendix C) subjects with CHF most commonly
endorsed phrases were: “I cannot get enough air” (n ^ 19, 63.3%), “I feel out of breath”
(n = 17, 56.7%), “My breathing requires effort” (n = 16, 53.3%), and “I feel I am
smothering” “I feel I am suffocating” (n =11, 36.7%).

57

Table 7
Descriptors Endorsed by 30 COPD and 30 CHF Subjects

Significance

COPD
n

CHF
n

I feel that my breathing is rapid

4

3

.000

My breath does not go out all the way

11

4

4.356

.037*

My breathing requires more work

7

10

.739

.390

My chest is constricted

7

3

1.920

.166

My breathing is shallow

6

9

.800

.371

My breathing requires effort

11

16

1.684

.194

I feel a hunger for more air

12

10

.287

.592

I feel that I am smothering

6

11

2.052

.152

My breathing is heavy

7

7

.000

1.00

I feel out of breath

20

17

.635

.426

My breath does not go in all the way

4

7

1.002

.317

My chest feels tight

9

9

.000

1.00

I cannot get enough air

14

19

1.684

.194

I feel that I am breathing more

3

6

1.176

.278

13

11

.278

.598

Descriptors

I feel I am suffocating
Note, p < .05
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X

1.00

Table 8
Descriptors Endorsed in the work/effort and suffocation Clusters
among COPD and CHF subjects
COPD (n =
Descriptors

30}

CHF (n = 30)
n(%)

n(%)
18 (60.0)

26(86.7)

My breathing requires more work

7 (23.3)

10 (33.3)

My breathing requires more effort

11(36.7)

16 (53.3)

Work/Effort Cluster

Suffocation Cluster

19(63.3)

22(73.3)

I feel I am smothering

6 (20.0)

11 (36.7)

I feel I am suffocating

13 (43.3)

11 (36.7)

Note. Degree of freedom in both clusters = 1
p < .05
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Significance
jL

2

5.454

.0195

.6932

.4051

There was no phrase that identified the breathing experience of CHF subjects
only. The other terms were similarly selected by both groups ( Table 7).
Question 3: Is there a difference in the terms COPD and CHF patients use to describe
their breathing discomfort?
The terms resulting from asking the patient what terms they used to describe their
breathing shows that among the most frequent descriptor in both groups, the descriptor
“Scary” was reported by the COPD group only. Other common terms were shared by
both COPD and CHF groups: “shortness of breath”, gasping, and I cannot get enough air
(Table 6) There were other terms unique to either COPD or CHF and groups but were
less frequently reported.
The analysis of the list of descriptors endorsed (Appendix C) showed that both
groups selected most of the phrases similarly to describe their breathing discomfort. The
phrase “My breath does not go all the way out” selected significantly more by the COPD
group (%2 =4.356, p = .037).
Table 8 reports the analysis of the clusters “work/effort” and “suffocation” that
were previously described in Simon et al. (1990). Both groups endorsed descriptor from
the effort cluster (i.e., “my breathing requires more work” and “my breathing requires
more effort”) and “suffocation” cluster (i.e, “I feel I am smothering” and “ I feel I am
suffocating”). However, the CHF group endorsed the “work” cluster significantly more
than the COPD group (x2 = 5.4545, p = .0195). The “suffocation” was similarly endorsed
by COPD and CHF subjects (x2 =0.6932, p = 0.4051).
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Question 4: What is the frequency of dyspnea in COPD patients?
The PFSDQ was used to gather the data to answer the question regarding the
frequency of dyspnea in patients with COPD and CHF. This questionnaire was used to
assess the incidence of dyspnea, the incidence of suffocation, and the frequency the
subjects in both groups experienced severe to very severe dyspnea (Table 9).
Most subjects with COPD reported dyspnea (n = 29, 96.7%). The mean frequency
subjects experienced severe to very severe dyspnea in a month period in the COPD group
was M = 13.14 (SD = 10.80). The frequency COPD was identified according to the
following categories: (a) 0 times (n = 8), (b) 1-5 (n = 9), (c) 6-10 (n = 3), (d) 11-25 (n 5), and (e) 25-40 (n = 5).
Question 5: What is the frequency of dyspnea in CHF patients?
Data gathered from the PFSDQ were used to answer this question. Most
participants with CHF (n = 25, 83.3%) reported experiencing dyspnea (Table 9). The
mean frequency CHF subjects experienced severe to very severe dyspnea in a month
period, was M = 12.14 (SD = 11.92). The frequency identified according to the
following categories: (a) 0 (n = 9), (b) 1-5 (n = 12), (c) 6-10 (n =1), (d) 11-25 (n - 6), and
(e) 26-40 (n = 6).
The incidence of dyspnea was not significantly different (p = .195) between
COPD and CHF groups (Table 9). Additionally, the frequency patients with COPD and
CHF reported experiencing severe to very severe dyspnea was not significantly different
(p = .788). Although the CHF group reported dyspnea less frequently than COPD
subjects there was not significant difference between the two groups (Table 10).
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Table 9
Dyspnea and Suffocation Experience in 30 COPD and 30 CHF Subjects

Dyspnea experience
Suffocation experience

CHF
n(%)

Significance
Test

COPD
n(%)
29 (96.7)

25 (83.3)

= 2.080

J95

23 (76.7)

12(40.0)

X2 = 6.918

.015

t = 0.270

.788

Frequency of S to VS dyspnea

£

Dyspnea Categories
1. 0

8 (26.7)

9 (30.0)

2. 1-5

9 (30.0)

12(40.0)

3. 6-10

3 (10.0)

1 (3.3)

4. 11-25

5(16.7)

2 (6.7)

5. 26-40

5 (16.7)

6 (20.0)

Note. Values enclosed in parentheses represent dyspnea intensity standard deviation of
mean values of intensity. S = Severe VS = Very Severe. Frequency was expressed as the
number of times per month. Intensity was measured on a 0-10 scale, 0 = no dyspnea, 1 -3
mild, 4-6 moderate, 7-9 severe, and 10 very severe. Mean dyspnea frequency between
groups was: COPD = 13.14±10.80 CHF = 12.14±11.92.
p < .05
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Table 10
Intensity of Dyspnea in COPD and CHF subjects

COPD (n = 30)
Nl(SD)
n(%)
4.63(2.09)

CHF (n = 30)
M(SD)
n (%)

Mild

8 (26.7)

21(70.0)

Moderate

16(53.3)

4(13.3)

Severe

6 (20.0)

5(16.7)

Intensity
Today

5.50(1.66)

Most days
Mild

4(13.3)

14(46.7)

Moderate

18(60.0)

11 (36.7)

Severe

8 (26.7)

5(16.7)
5.40(1.99)

Day-to-day
Mild

6 (20.0)

15 (50.0)

Moderate

17(56.7)

12 (40.0)

Severe

7(23.3)

3 (10.0)

Significance
t

£

2.63(2.62)

2.426

.018

4.10(2.59)

2.459

.017

3.50(2.13)

2.499

.015

Note. Dyspnea Intensity among the COPD and CHF group significantly different with an
conservative approach “today” (^ =7.938 p = .019), “most days” {%_ =13.512 p = .001),
and day-to-day (xi= 6.319 p = .042 ).

63

Question 6: What is the intensity of dyspnea in patients with COPD?
Data gathered with the PFSDQ was used to answer this question the intensity of
dyspnea in the COPD group. The subjects reported dyspnea in three different occasions:
“today”, “most days in the past year”, and “most day-to-day activities (Table 10).
In the COPD group the mean of the intensity in three different occasions were: (a)
“today” (M = 4.63, SD = 2.09), (b) “most days of past year” (M = 5.50, SD = 1.66), and
(c) “most day-to-day activities” (M = 5.40, SD =1.99). Most COPD participants reported
moderate level of dyspnea “ today” (n_=16, 53.3%,), 8(26.7%) reported mild dyspnea,
and 6(20.0%) reported severe dyspnea. On “most days of the past year” they reported
experiencing moderate dyspnea (n_=18, 60.0%), severe (n_= 8, 26.6%), and mild (n_= 4,
13.3%). On “most day to day activities” they reported having moderate dyspnea (n_= 17,
56.7%), severe (n_= 7, 23.3%), and mild (n = 6, 20%).
Question 7: What is the intensity of dyspnea in patients with CHF?
For the CHF group, Table 10 reports the dyspnea intensity in three different
occasions: (a) “today” (M = 2.63, SD = 2.62), (b) on “most days of past year” (M =
4.10, SD = 2.59), and (c) “most day-to-day activities” (M = 3.50, SD = 2.13). The
majority of CHF participants reported having mild dyspnea “today” (n_= 21, 70%), severe
(n_= 5,16.6%), and moderate (n_= 4,13.3%) dyspnea. On “most days of the past year”
most participants reported mild (n_= 14, 46.7%), moderate (n_= 11, 36.7%), and severe (n
= 5,16.7%) dyspnea. On most day-to-day activities they reported mild (n = 15, 50.0%),
moderate (n_= 12, 40%), and severe (n_= 3, 10%,) dyspnea.
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Intensity of Dyspnea on COPD versus CHF
There was a significant difference on the report of intensity between the groups
(Table 10). The results indicated patients with COPD experience a higher intensity of
dyspnea than CHF patients.
Subjects with COPD experienced moderate levels of dyspnea in all three
occasions while CHF reported mild dyspnea on two occasions and moderate in one
occasion (Table 10). Dyspnea intensity was significantly higher in the COPD group on
three different occasions on Chi-Square test (p< .05). Two-tailed t-test was also found
statistically significant (p < .05) for dyspnea experienced “today”(t = 2.459, p < .017) the
“past year”(L= 2.426, p < .018) and in “most day to days activities” (t = 2.499, p < .015).
Other Findings
The second question of the PFSDQ addressed the item/variable “suffocation” in
the subjects breathing experience: “Have you ever experienced such severe shortness of
breath that you thought you would suffocate?” (Appendix A). Subjects with COPD (n =
23, 76.7%) reported having experienced suffocation significantly more frequent than
CHF subjects (n =12, 40.0%). Suffocation was significantly higher
the COPD population (Tables 9 and 10).
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6.918, p < .015) in

DISCUSSION
This study of dyspnea descriptors in patients with pulmonary and cardiac
conditions attempted to investigate (a) the common terms patients with COPD and CHF
use to describe their breathing discomfort (b) identify the frequency of dyspnea, and (c)
intensity of dyspnea in these populations. A sample of 60 stable patients with COPD (n_=
30) and CHF (n = 30) was utilized to examine these questions. The results provided
further understanding of the dyspnea experience in these populations. The following
findings summarize the results obtained:
1. There were differences in the terms patients with COPD and CHF used to
describe their breathing discomfort.
2. The incidence of dyspnea between the COPD and CHF groups was similar.
3. The frequency patients with COPD and CHF experience severe to very severe
dyspnea was similar.
4. The reported intensity of dyspnea in COPD patients is higher than that of CHF
patients.
The following sections present the discussion addressing each one of the research
questions. Demographics and other findings are also discussed.
Population Characteristics and Symptom Report
There are some factors that may influence dyspnea in patients with pulmonary or
cardiac conditions reported in the literature such as gender, culture or ethnicity, language,
socio-economical status and education (Janson-Bjerklie et al.,1986; Simon et al.1990;
and Hardie et al., 2000). Additionally, intensity of dyspnea experienced at the day of the
interview is an important factor influencing patient’s recall of past dyspnea although the
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recalling of past experience was accurate when compared to recent experience (Meek,
Lareau and Anderson, in press). It is still unknown if this finding also applies to the CHF
population.
The setting and inclusion/exclusion criteria of this study may have “controlled”
for some of the above factors influencing dyspnea. For example, this study took place in
an institution that provides care for veterans who have similar access to health care and
medication. Having equal access to health care and medication may have “controlled”
this socio-economical difference that could be important in a different sample affecting
patient’s condition. For this reason no further information on the socio-economical
status was gathered from the participants.
Gender is another factor that seems to influence patient reports of their breathing
experience. Although the inclusion criteria was gender inclusive, all the participants
enrolled were male. The few women that were enrolled in the clinic at the time did not
meet the criteria for the study. A lower number of female patients are enrolled in both
Pulmonary and CHF clinics. JLVAMC statistics indicates 32030 males and 3808 females
are enrolled in this facility making it difficult to recruit female patients that meet the
inclusion criteria for this study (A. Benson, personal communication, August 29, 2001).
Although the inclusion/exclusion criteria was ethnicity inclusive mostly
Caucasian males were recruited. Although most of the participants in each group were
also Caucasians there was a significant difference in the ethnicity variable between the
COPD and CHF groups. Patients in the CHF group had a closer representation of the
general population of patients in that institution although minority groups were still
underrepresented. The COPD had a lower representation of other ethnicity groups having
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the Caucasian population represented above the average for the institution. It may be that
the reason there was a greater number of African American participants in the CHF group
is because heart failure is more predominant in the black population due to hypertension.
Language is another factor that was controlled by the inclusion /exclusion criteria
that enrolled only patients able to read, write, and understand English. Because this study
did not aim to address different languages but different descriptors used in the English
language to describe breathlessness, the instruments utilized were in English.
Additionally, limiting the language to English is a reasonable inclusion /exclusion criteria
for this sample since individuals enrolled in the military service are required to read and
understand English.
Another factor that may influence dyspnea is the patient’s health status. It has
been shown that patient reports of dyspnea intensity on the day of the interview was the
most important factor contributing to the variance between actual and recalled dyspnea
(Meek et al., in press). Considering that patients with COPD and CHF could have
presented with acute breathing discomfort or exacerbation, individuals that had been
hospitalized in the last four weeks before the data collection were excluded. Only stable
COPD and CHF participants diagnosed for at least one year were included in this study.
This provided a sample likely to be experiencing a similar health status.
Other demographic characteristics of this population are education, marital status,
and age. In this study, there were no significant differences in the marital status of the
COPD and CHF participants. There was a significant difference in the age of the
participants, with the CHF group younger than the COPD. Until now age has not been
identified as a variable directly influencing the report of dyspnea descriptors frequency or
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intensity. On the other hand it has been reported that aging influences how early older
patients manage their symptom and seek medical help. For example a belief that
symptoms, such as dyspnea, are a normal consequence of aging is commonly reported in
the elderly population. Patients that believe this may delay seeking assistance in response
to dyspnea, leading to increased discomfort (Silvestre & Mahler, 1993). Since this study
was limited to stable patients the influence of age on symptom reports were controlled.
Comorbid conditions are another variable that could interfere with patient
interpretation and report of their breathing difficulty. Since this study sought to identify
dyspnea in patients with COPD and CHF, it was important to establish that patients did
not have other conditions that could directly affect their breathing such as neurological,
skeletal, or other conditions that may increase breathing discomfort. The comorbid
conditions, for the CHF group, seemed to reflect the risk factors of their primary
diagnosis. The medications used seemed appropriate for each condition. Only one patient
with CHF was receiving pulmonary medication. Regarding oxygen use, half of the
participants were on oxygen while none of the CHF participants were using oxygen. The
findings suggest hypoxia was more common in the COPD population which is consistent
with previous findings in the COPD population (Ailani et al., 1999, p.l 104). On the other
hand a screening for hypoxia did not occur in the CHF population. Screening may have
determined if hypoxia was also a important problem in the CHF group.
Because of the many variables that may influence patient’s interpretation and
report of their symptoms, being able to control for some of these differences may be
important for the study of the language of breathlessness in the COPD and CHF
populations.
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Dyspnea Descriptors in the COPD and CHF Populations
The findings from this study support the literature indicating that patients with
different conditions experience breathlessness qualitatively different and use different
terms to describe their breathing discomfort (e.g. Simon et ah, 1990, Elliot et ah, 1991,
Mahler et ah, 1996). The report of descriptors in response to the first question of the
interview questionnaire (Appendix B) and the endorsement of descriptors from the list
(Appendix C) demonstrated “features” previously identified by Simon and colleagues.
These “features” are (a) multiplicity: more than one cluster of descriptors are selected to
describe their breathing discomfort, (b) uniqueness: there are unique descriptors that can
be associated to a condition, and (c) sharing: there are descriptors that can be shared or
associated to more than one condition (Simon et ah, 1990, p. 1012).
Multiplicity was found in both volunteered and endorsed descriptors in the
COPD. The results showed that participants with COPD and CHF volunteered more than
one term to describe breathing discomfort and thus displaying the feature “multiplicity”.
For example, some of the terms used by COPD and CHF reporting different breathing
sensations were “hard to breathe”, “gasping ”, “tightness”, and “exhausting”. Further, the
terms endorsed from the list of descriptors (Appendix C) also reported this feature of
multiplicity since all descriptors in the list were selected by at least once COPD and CHF
patients. These results were consistent with previous studies that found patients with
different conditions selected more than one descriptor or cluster of descriptors to describe
their breathing discomfort (Simon et al., 1990, Elliot et ah, 1991, and Mahler et ah,
1996).
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In referring to the unique features of dyspnea descriptors, this study found that
patients with COPD and CHF reported descriptors that were unique to their condition.
For example, only patients with COPD volunteered the descriptor “scary” (i.e., the most
common descriptor in this group) and “choky”. Previous studies have not reported
“scary” or “choky” as a breathing descriptor.
The unique descriptors volunteered by the CHF group were: “tiredness”,
“suffocation”, “heaviness”, and “feeling winded”. Previous studies have found the
descriptor “winded” unique to the cardiac population while the descriptors “tiring
suffocation” and “heavy” were also reported by the COPD group. CHF patients, were one
of several cardiac condition included within the cardiac group studied by Elliot et ah,
(1991), therefore true comparisons with this work could not be made.
The endorsement of all the descriptors (Appendix C), show there was no unique
term endorsed by COPD or CHF only. On the other hand, the descriptor “my breath does
not go all the way out” was endorsed significantly more by COPD participants. This
finding differs from Simon et ah, (1990), who using a similar list of descriptors, found
terms unique to the COPD and CHF patients. In Simon et ah, only COPD patients
endorsed the terms “My breathing requires effort” and “My breathing requires more
work” while CHF patients only endorsed the terms “I feel that my breathing is rapid”, “I
feel that I am smothering”, and “I feel that I am suffocating”.
The feature “sharing” is also demonstrated in this study. A majority of the
descriptors volunteered were shared by both groups (Table 5). For example the descriptor
“Shortness of breath” was one of the most frequent descriptors volunteered and shared in
both groups. These findings are in agreement with Parshall (1999). Elliot et ah (1991) in
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the other hand identified this descriptor in COPD group only. The endorsed descriptors
also demonstrated the “sharing” feature. All descriptors were selected by both groups
although one of the descriptors was endorsed more significantly frequently by the COPD
group. The descriptors “work” or “effort” was reported in both groups agreeing with
previous studies (Mahler et al., 1996, Parshall,1999) but different from other studies
which have found the descriptor “ work” or “effort” unique to the COPD group only
(Elliot et al.,1991 and Simon et al.,1990).
The analysis of the clusters “effort” and “suffocation”, from the list of descriptor
(Appendix C), was shared by both groups. This study found that the COPD group
endorsed the descriptor under the suffocation cluster more than the CHF group while
both groups endorsed the “work” cluster similarly. This finding differs from a previous
study utilizing a similar list of descriptors where the cluster “effort” and “suffocation”
were endorsed only by COPD and CHF patients respectively (Simon et al., 1990). This
difference could be related to the larger representation this study have of the CHF
population. Also this study have included stable patients with COPD and CHF while
others have included both unstable and stable groups.
Summary
The most common breathlessness descriptors volunteered by COPD participants
were: “Scary”, “Hard to breathe”, “Shortness of Breath”, “Gasping”, “Difficult
breathing”, “Wheezing”, and “My breath does not go all the way out”. Among the CHF
participants the most common breathlessness descriptors were: “Shortness of Breath”,
“Gasping”, and “Cannot get enough air”. Among the most common descriptors
volunteered by the COPD and CHF group, all except “Scary” have been previously
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reported in the literature (e.g. Parshall, 1999, Mahler et al, 1996, Elliot et ah, 1991). The
descriptor “Gasping”, among the most common terms volunteered, are not included in
the list of descriptors the participants endorsed in this study (Appendix C).
All the terms from the list of descriptors were endorsed but both groups, “my
breath does not go all the way out was endorsed significantly more frequently by the
COPD group. Different from previous findings where these terms were not report by
neither group (Simon et al., 1990) or were reported only in the CHF group ( Mahler et al.,
1996). The descriptor “ my breath does not go out all the way” seems to reflect the
experience of COPD patients whose breathing is affected by changes in the lung tissue
caused by inflation (Manning & Schwartzstein, 1995).
Further, the analyses of the descriptors in the cluster “suffocation” and
“work/effort” from the list of descriptors showed patients with CHF endorsed the
“work/effort” cluster more than the COPD group while both groups endorsed the cluster
suffocation differently. This is an interesting finding taking into consideration that studies
that utilized the same list of descriptors found that descriptors from the cluster
“ work/effort” were endorsed by COPD patients only. Additionally, when assessing the
suffocation experience with the PFSDQ, patients with COPD reported suffocation
significantly more frequently than the CHF patients (Table 9). Since “suffocation” has
been more frequently associated to the CHF and “work/effort” descriptors to patients
with COPD, these descriptors should be further investigated these populations by
studying also the literal words used by patients. Interestingly, the term suffocation was
not verbalized by either group when reporting their own words but were endorsed from
the list of descriptors and checked from the PFSDQ. These findings suggest there may be
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a difference between the volunteered terms, endorsed terms and the report of
“suffocation” experience in these population.
These findings suggest that some of the common terms used by patients with
COPD and CHF may not be known to clinicians treating these patients. Since patient’s
reports of dyspnea are often used to make clinical judgments it is important to be aware
of the terms used by these patients use to describe their experience. The utilization of a
list of pre-designed list of descriptors may exclude some important terms such as the
affective terms (e.g. “Scary”) or lead patients to give a biased description of their
symptom.
The differences found in this study, may be attributed to the differences in the
methods. For instance, patients were asked to recall their breathlessness during exercise
(Elliot et al., 1991), recall their experience provoked by activities (Mahler et ah, 1996), or
at rest (Simon et ah, 1990).
The acuity of the patients may also influence terms used. For instance some
studies included inpatient, outpatient or both. This study addressed dyspnea in patients
that were stable. Also, the question asked did not specify if discomfort occurred at rest or
during activity differing from the studies addressing dyspnea during exercise.
Another important factor affecting the methodology of studies on dyspnea
descriptors is the utilization pre-established list of descriptors which may present a
limitation for the identification of the terms patients with COPD and CHF utilized to
describe their breathlessness. This study identified and report the exacted words patients
used as well as terms endorsed by the participants while other studies utilized list of
descriptors and reported only terms endorsed by the participants.
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Frequency of Dyspnea in COPD and CHF Patients
Although the literature suggests dyspnea is reported by most patients with COPD
and CHF (Parshall, 1999), previous studies have not identified the frequency of dyspnea
in these populations. The findings of this study shows most of patients with COPD and
CHF experience dyspnea. The findings did not support there was a difference in the
incidence of dyspnea in the population of stable COPD and CHF patients. Even though
the difference was not significant, the percentage of patients reporting dyspnea was
higher in the COPD group (96.7%) than in the CHF (83.3%). This study found that the
percentage of patients that reporting dyspnea is higher than the percentages found in
previous work (Lareau et al., 1994, Parshall, 1999).
In addressing research questions 4 and 5, this study found there was no difference
in the frequency patients with COPD and CHF experienced severe to very severe dyspnea
even though clinical experience seems to indicate that stable patients with COPD
experience dyspnea more frequently than stable CHF patients. This may be because
during the data collection patients had a hard time answering this question. As phrased,
the question addressed the frequency of severe to very severe symptom, and the subjects
usually tried to associate an answer with activities performed. For example they would
state “if I am very active I would experience more often but if I do not do much it is low”
and that it was “a difficult question to answer”. These findings may accurately reflect the
experience of stable COPD and CHF population or could be different if the question was
phrased more specifically.
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Dyspnea Intensity in the COPD and CHF Population
Although there has been evidence patients can accurately recall their dyspnea
intensity (e.g. Mahler, et al. 1996; Stulbarg et ah, 1999, Meek et ah, in press), little is
reported on the intensity of dyspnea in patients with COPD and CHF. The findings
indicated that dyspnea intensity in COPD patients is significantly higher than in CHF
patients. Dyspnea intensity has not been previously compared in a group with similar
number of COPD and CHF patients. Studies that have reported on the dyspnea intensity
in COPD and CHF patients have a lower representation or not reported the significance
of the difference between intensity among these patients. No previous studies have
compared the dyspnea intensity on both groups in three different occasions.
The COPD participants reported moderate dyspnea on three different occasions
(e.g. 4-6 in a 1-10 scale): “today”, “in most days of past year”, and in “most day-to-days
activities”. A study utilizing the same measures found similar intensity in COPD
patients on most days and in most-day-to-day activities (Lareau et ah, 1994). These
values may accurately represent the experience of most COPD patients with severe to
very severe condition. This idea is supported by previous studies that studies that have
not found correlation between dyspnea and the decline in pulmonary function (Eakin,
Kaplan, Ries, & Sassi-Dambron,1996, Lareau et ah, 1999). On the other hand there is
still a large number of patients in both extremes experiencing mild or very severe
dyspnea.
Other studies have reported different levels of intensity in the COPD population.
For example, patients with advanced COPD had dyspnea intensity varying from severe
breathless (M = 2.5, SD = 1.5) to mildly to moderately breathless (M = 8.5 , SD = 1.5) in
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the baseline dyspnea index (BDI) ranging from “O” very severe breathless to “12”
unimpaired (O’Donnel & Webb, 1992). Another study found that the usual score of
dyspnea in the COPD group was (M = 35.6, SD = 17.8 ) on the Dyspnea Visual Analog
Scale (DVAS) ranging from 0 (no breathless at all) to 100 (extremely breathless) while
the worst score reported was (M = 72.2, SD = 19.9) ( Janson- Bjerklie et ah, 1986).
Although the DVAS and BDI have different measurements their scores could be
compared. For example a 8.5 on the BDI could correspond to 35.6 on the DVAS since
both seem to identify a “mild breathlessness”.
Another study (Mahler et al., 1996) has found that patients with COPD reported
severe breathlessness and CHF reported mild to moderately breathlessness. CHF patients
reported greater dyspnea intensity (M = 5.7, SD = 2.6) than COPD patients (M = 4.3, SD
= 2.1) on the BDI, a 0-12 scale (0 = very severe and 12 = unimpaired). Although the
values of the BDI are higher for the CHF group the significance of this difference was not
reported. Further, patients with COPD and CHF reported having moderate to moderately
severe dyspnea (e.g. 5-8) in a 0-1 Orange of the Borg Scale. The difference between the
COPD and CHF groups was not reported (Simon et al.,1990).
These findings identify more clearly the intensity of dyspnea between these
groups . In previous studies the intensity of dyspnea in COPD and CHF patients had not
been identified or were limited because the number of participants in each group. Also
the few studies that reported dyspnea intensity in COPD and CHF patients did not
reported the significance of the difference between groups.
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The Symptom Interpretation Model and the Study
The Symptom interpretation model was useful in understanding the processes that
may be utilized by COPD and CHF patients in interpreting their symptoms. Considering
the first construct of the model “input”, this study acknowledges that the changes in their
internal and external environment contributed to their awareness of breathing discomfort.
For example the pathophysiological changes caused by their chronic conditions (internal
changes) and the environment around them triggering breathlessness (e.g. such as
activities performed). Subjects often referred to this association when answering the third
question of the PFSDQ.
Taking in consideration the second construct of the SIM “interpretation”, this
study assumes that COPD and CHF patients labeled their dyspnea based on the memory
stored of past experiences utilizing conceptual identification, prototypes knowledge
structure and heuristic reasoning. For example when patients reported the intensity of
their dyspnea today, on most days, and on most day-to day activities they made
judgments of their experience based on the central tendencies of their past experience
rather than using an single experience. Further when reporting the terms they utilized to
describe their breathing discomfort the same interpretation process could be utilized.
Additionally, “heuristic reasoning”, also part of the interpretation construct, was used
when participants in both groups compared similarities between dyspnea events in three
different situations. For instance, patients had to differentiate “ today” dyspnea
experience from “ most days” and “most-day to days”.
Regarding the third construct of this model. This study assumes that because the
participants have been diagnosed for at least a year, they have already made important
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“choices” concerning their disease (e.g., treatment) based on the interpretation of their
breathing discomfort and treatment. The changes that occurred in the internal and
external “environment” of these patients affected how patients perceived their breathing
discomfort. Finally all the constructs or “phases” of this model seem to have been utilized
by COPD and CHF patients when interpreting their breathing experience.
General Nursing Implications
This study has implications that can be utilized in two levels of nursing : at the
baccalaureate level and at the advance practice. Because dyspnea is a common symptom
in the COPD and CHF population, there is a need for a clear understanding of this
symptom among the nursing profession. The understanding of the terms patients use to
describe their symptom, the frequency, and intensity of dyspnea is knowledge that can be
utilized in various levels of care and different settings. The phases of the nursing process
will be used to guide these implications.
Assessment. In assessing dyspnea in COPD and CHF population, nurses should
attempt to obtain the exact words patients use to describe their breathing. Although using
a predetermined list of descriptors could help patients who are having difficulty
expressing their breathing discomfort; it is important to listen to the exact words patients
use. In the COPD group the most frequent descriptor volunteered (i.e, “scary”) could be
unknown if the exact word patient utilized to describe their breathing was not noted. The
descriptor “scary” is not included on the lists of breathlessness descriptors utilized in
previous studies. Further, it is critical to be aware of nurses own perceptions and biases
regarding the terms patients would use to report their experience, in order not to
compromise an accurate assessment of dyspnea.
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Diagnoses. Although the focus of this study was the stable COPD and CHF
patients, nurses caring for individuals in various areas make individualized nursing
diagnoses of patients breathing based on what they observe or patients report.
Contemplating this phase of the nursing process and the findings of this study, it is
important to address patients needs as a whole not focusing only on the physical aspects
of dyspnea in patient with COPD and CHF. Although the affective descriptor was among
the most frequent in the COPD group, the CHF group also reported affective descriptors
(e.g., panicky) that should be addressed in these patients. Additionally, in the phase it is
important to note to the unique and shared descriptors that are used by COPD and CHF,
however not assuming that all patients with these conditions experience dyspnea or
utilize a certain kind of descriptor to describe their condition.
Planning. When planning care for individuals with COPD and CHF experiencing
dyspnea nurses can apply the knowledge of this study. For example knowing that patients
with stable COPD experience a greater intensity of dyspnea, nurses can plan their
intervention with these patients in order to avoid inactivity leading to deterioration or
over exertion. Patients experiencing dyspnea can learn to live with their limitation by
adopting behaviors that allow them to be function within their disability. For example,
when planning the care for a patient with severe COPD versus a patient with normal lung
function, nurses should understand that the COPD patient may need more time to
perform activities. Although the COPD patient will be able to perform a given activity
he/she will probably have to stop and rest while performing the activity.
Intervention. Nurses assisting patients with COPD and CHF in different settings
may have rapid access to a multidisciplinary team, such as in a hospital setting, or work
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more individually, such as in the homecare nursing. They will be implementing
interventions or suggest other interventions to other members of the multidisciplinary
team. These interventions should address the multiple aspects of dyspnea such as
physical and affective aspects. The importance of addressing the individual as a whole
has been highlighted in previous phases of the nursing process. A study reporting what
patients expect from nurses when addressing their symptom helps to expand this concept
on the importance of addressing the affective aspects of dyspnea: patients expected
nurses to provide treatment for the physical aspects of dyspnea and also “acknowledge
and believe” in the symptoms they reported (De Vito, 1990). By implementing
interventions taking in consideration the multiple aspects of dyspnea, a more effective
care can be provided.
Evaluation. In continually evaluating the client with breathing experience nurses
can address the current sensation experienced by these patients The SIM model shows
that internal and external environment of the patient may influence how they perceive
and interpret their symptom. By considering the many factors that influence their
symptoms nurses can have a better picture of their client and be able to communicate
with other members of the multidisciplinary team in order to plan and implement
appropriate interventions. Additionally current tools already available to assess dyspnea
should be incorporated among the other vital signs especially in units where dyspnea is a
common symptom.
Implications to Advance Practice Nursing
Advance Practice Nurses use theories and models to understand phenomena that
is contemplated in a different perspective than by the baccalaureate nurse. Besides the
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above applications that can be done in the baccalaureate level, nurses in advanced roles
can utilize the SIM as a framework to guide their understanding of symptom
interpretation in patients with breathing discomfort. This model is useful to understand
not only dyspnea but all symptoms.
Brown, (2000) proposes five characteristics of the care provided by Advanced
Practice Nurses (APNs): (a) use of holistic perspective, (b) formation of partnership with
patients (c) expert clinical thinking and skillful performance (d) use of research based
practice (5) and use of diverse approaches to health and illness management. Although
these characteristics are important, when caring for individuals with chronic disabilities,
using a holistic perspective, formation of partnership with patients, and using a research
based practice have an especial value when thinking of the interface of nurse-patient.
The importance of a holistic approach to patients experiencing breathlessness
have been already discussed due to the multiple features this symptom has. Forming a
partnership with patients it is another important characteristic that have shown to result in
improved health outcome (Raudonis & Acton, 1997, Watson, 1997). Although APNpatient partnership may be challenged by patient’s cultural differences or patients unable
to fully participate in a partnership (e.g., unconscious or mentally ill patients), APNs
should give patients this opportunity of becoming partners in their care. Further when
using a research based practice approach, APNs are able to incorporate in his/her daily
practice research findings pertinent to the area of practice. An APN has preparation to
analyze, critique and select research works that are appropriate and that will bring benefit
patients to the patients under his/her care.
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Study Limitations
The first limitation of this study is related to our sampling procedure that used a
purposive sample of 60 patients. Using a purposive sample of the population the results
may limit generalizability to other populations, however this study was powered and had
better representation of the COPD and CHF populations than previous studies. In studies
that have included even a larger population of COPD participants, the CHF group have
been underrepresented. Additionally this is the only study until the present addressing
breathlessness descriptors that has interviewed this number of patients and reported the
exact words patients use to describe their breathing discomfort.
The influence of ethnicity and gender on dyspnea cannot be predicted at this time
in patients with COPD and CHF. Racial and gender diversity could not be attained due to
a This impossibility is due to a lower enrollment of other ethnicities in the VA health
system compared to the Caucasian population and the lack of female participants who
met the inclusion criteria. The female gender having not represented in this study, may be
a reflection of male to female ratio(i.e., 8:1) of patients at the institution where the study
took place
Recommendations for Further Investigation
Based on the findings from this study, the following recommendations are made
for research, practice and education of health care providers diagnosing and treating
patients with COPD, CHF or both diagnosis. Considerations should be given to the
following suggestions:
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Research
1. Obtaining a sample that represent male and female patients and different
ethnic background. Studying a sample that better reflect the general
population of patients with moderated to severe stable COPD and CHF would
provide more reliable results related to the terms these groups use to describe
their breathlessness.
2. The study of dyspnea in stable patients with mild COPD and CHF would
provide a better understanding of dyspnea in patients with mild conditions.
Since COPD patients with mild lung impairment can still experience dyspnea
it would be interesting to understand the terms they use to describe their
breathing and the reported frequency and intensity of dyspnea in this
population. Although the NYHA indicates that class I CHF patients do not
experience dyspnea with ordinary activities, it would be interesting to identify
the occurrence and characteristics of breathing discomfort in this population
of stable class I CHF patients.
3. Identifying breathlessness descriptors in COPD and CHF patients , who have
been recently diagnosed would enhance the understanding of dyspnea in this
population. Patients who are recently or diagnosed for a short period of time
may not have learned the common terms or jargons used by health to describe
difficult breathing (e.g., shortness of breath).
4. Identifying dyspnea with activities of daily living would bring a more accurate
knowledge of the frequency and intensity of dyspnea in patients with COPD
and CHF. For example in this study, patients have indicated that it is difficult
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to determine specifically the frequency of dyspnea in a month period without
thinking abut the amount or kind of activity performed.
e.g. Patients in both group when answering the third question of the PFSDQ
“how often do you experience severe to very severe shortness of breath?”
would express that the question was very hard to answer because it depended
on how active they were. Many would avoid activities as to avoid dyspnea.
Those who avoided activities that “exerted them” seemed to report a lower
frequency of dyspnea. Additionally when assessing frequency, it seems to be
important to identify the type of dyspnea. In the questionnaire patients were
asked only about the severe to severe experience.
5.

Identify clearly symptom management and coping in patients with COPD and

CHF experiencing breathlessness. This knowledge would empower health
professionals caring for patients with these conditions where dyspnea is a major
symptom. Effective coping strategies, leading patient to wellness, should be
encouraged while harmful strategies should be discouraged.
Education and Practice
Dyspnea is experienced differently by patients with COPD and CHF. This
difference was noted on the descriptors patients with COPD and CHF used to describe
their breathing and the intensity they experience dyspnea. By knowing patients
experience dyspnea differently nurses and other members of the healthcare team can
enhance their care. The following recommendations are suggested:
1.

Patients with CHF should be screened for pulmonary causes of dyspnea. Risk
factors often found in the CHF group such as cigarette smoking can cause
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pulmonary damage leading to dyspnea. Additionally, the lack of pulmonary
screening in these patients may cause that their source of dyspnea are
mistakenly addressed, e.g. administration or increasing diuretics in order to
treat shortness of breath in patients with heart failure while patient’s may not
have been experiencing breathing discomfort caused by fluid overload.
2. Educate professionals that dyspnea is more intense in the COPD than in the
CHF patients. Although in the clinic practice patients with COPD seem to
experience dyspnea on a “more continuous base” than CHF this study showed
that the significant difference occurred in the intensity of but not in the
frequency patients experienced dyspnea.
3. Nursing professionals in contact with COPD and CHF patients in many levels
of care should be educated regarding dyspnea assessment and the different
descriptors used by patients with different conditions experiencing breathing
discomfort. Considering the many factors that may trigger dyspnea, it is
important to take in consideration this many factors during assessment and
treatment of dyspnea. For example, this study has shown that being aware of
the affective components is very important in addressing dyspnea of patients
with COPD.
4.

The assessment of breathing discomfort should be among the “vital signs
assessment”. Considering that some patients may believe their breathing
difficulty is a normal consequence of aging, nurses should assess, educate, and
encourage patients to verbalize their breathing discomfort. By early
assessment and treatment, further complications could be prevented.
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Conclusion
This study addressed descriptors, frequency and intensity of dyspnea in the COPD
and CHF population have found: (a) patients with COPD and CHF use unique, multiple
and similar terms to report their breathing experience; affective terms were reported
within the most important descriptor in the COPD group, (b) the frequency of dyspnea in
COPD and CHF patients is similar (c) the intensity of dyspnea is higher in the COPD
population Considering the impact of dyspnea in COPD and CHF patients, this study has
brought new understanding of dyspnea for this population.
Previous studies of the dyspnea descriptors have brought important information
that has broadened the understanding of this symptom. Until the present no study had
addressed the language of breathlessness in the COPD and CHF population only. The
studies that included COPD and CHF did not have a significant number of participants or
did not study terms collected directly from patients. Others did not make distinction of
the diseases included under the cardiac or pulmonary category. This knowledge has
important clinical implications for the nursing profession, other health professionals, that
hopefully will benefit COPD and CHF patients and society as a whole.
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Appendix A
Jerry L.Pettis VA Medical Center
Pulmonary Functional Status & Dyspnea Questionnaire
SHORTNESS OF BREATH ASSESSMENT
ID =

Date =

INSTRUCTIONS:
The following questions relate to your discomfort in breathing. Please
check the most accurate answer.
No

Yes

1. Do you ever experience shortness of breath?

2. How many times a month do you experience severe to very severe shortness of breath?

3. How many times a month do you experience severe to very severe shortness of breath?

Using the following scale, place a mark on the line between 0 (no shortness of breath) to 10
(very severe shortness of breath) in response to the following questions.
4. Indicate how you've felt on most days during the past year.

No shortness
of breath

Severe

Moderate

Mild
I---- 1------ F
0 1
2

+

+

+

3

4

56

Very severe

1------ 1------ 1------ 1
789 10

shortness
of breath

5. Indicate how you feel today.

No shortness
of breath

I----- 1
0 12

Severe

Moderate

Mild

Very severe

+

+

I-------1------ 1------ 1------ 1------ 1

3

4

5

6

7

8

9

10

shortness
of breath

6. Indicate how you feel with most day-to-day activities.
Mild
No shortness
of breath

I---- 1------ 1------ 1
3
0 1
2

Moderate

+

+

Severe

I------ 1------ 1------ 1------ I
56
789 10

4
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Very severe
shortness
of breath

Appendix B
Interview Questions

Interview questions
1. Which words would you use to describe your breathing when it is uncomfortable?

2. Please choose from this list the top three phrases that best describe your breathing.

3 . Are there any other phrase from this list that you would like to add to the phrases you
have chosen?
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Appendix C
List of Descriptors
Put a check mark next to the phrases that describe your breathing. If you chose more than one
phrase to describe your breathing please write the numbers “1”, “2”, and “3”. For example, place
the # 1 near the phrase that best describes your sensation, # 2 for the second best, and # 3 for the
third best descriptor (“3”). If only one or two phrases seem appropriate, you should only select
those phrases (in other words you do not have to pick three phrases).
I feel that my breathing is rapid
My breath does not go out all the way
My breathing requires more work
My chest is constricted
My breathing is shallow
My breathing requires effort
I feel a hunger for more air
I feel that I am smothering
My breathing is heavy
I feel out of breath
My breath does not go in all the way
My chest feels tight
I cannot get enough air
I feel that I am breathing more
I feel I am suffocating

97

Appendix E
LOMA LINDA VAMC RESEARCH CONSENT FORM
SSN

SUBJECT NAME:

PRINCIPAL INVESTIGATOR: Suzanne C. Lareau, RN, MS
TITLE OF STUDY: Breathlessness Descriptors in Patients with Chronic Obstructive Pulmonary
Disease versus Congestive Heart Failure

LAY TITLE: Differences in describing breathing distress in patients with lung and heart
problems
DESCRIPTION OF RESEARCH
1.

Purpose of study and how long it will last:
You are being asked to participate in a study to better understand words patients use to

describe breathlessness (also called shortness of breath). This study is being done in partial
fullfillment of the requirements for Graduate School by the co-investigator. The purpose of
this study is to better understand breathlessness in patients with Chronic Obstructive
Pulmonary Disease (COPD) and Congestive Heart Failure (CHF). A total of 60 subjects will
be enrolled in this study from the Jerry L. Pettis VAMC. Each subject will be asked to meet
with the co-investigator to answer questions and complete two (2) brief questionnaires, on the
day of their regularly scheduled appointment.
2.

Description of the study including procedures to be used:
You will be asked to meet with the co-investigator, Ms. Adelaide Caroci RN, BSN for

approximately 15 minutes. During that time, she will ask you questions about your marital
status, education, and a list of your health problems. She will then ask you to describe the
words you use to describe your breathing when it is uncomfortable. You will then be

99

presented with a list of 15 phrases commonly used to describe breathlessness. You
will be asked to chose the three that best describe your breathing when you are having
difficulty. This should take five minutes or less. Lastly you will be asked to complete a six
item questionnaire describing your breathing. This should take two minutes or less. The total
amount of time to complete all of these questions should take no more than 10 minutes.

3.

Description of any procedures that may result in discomfort or inconvenience:

4.

Potential risks of the study: None

5.

Potential benefits of study: None

6.

Other treatment available: Not applicable

7.

Special circumstances: None

8.

Withdrawal from the study:

None

It has been explained to you that you do not have to take part in this study and are free
to withdraw at any time. Your decision not to participate or to withdraw will involve neither
penalty nor loss of VA or other benefits to which you might be otherwise entitled.
9.

Confidentiality/Use of research results:
Although the information obtained about you during the research study will be kept

strictly confidential, the information will be available to persons connected to this study, and
may be released to agencies as required by law, such as the Food and Drug Administration
(FDA).
The results of this study may be published, but your identity will not be revealed in
any publication without your permission.
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10.

Questions or concerns related to the study:

You have /have not participated in a research study within the past three (3) months.
Your participation involved:

If you have any questions about the availability of medical care of if you believe you
have experienced a research-related injury as a direct result of participation in the study, you
should immediately contact
Suzanne Lareau at (909) 825-7084 ext. 3095 during the day and
Suzanne Lareau at (909) 825-7084 after hours and ask the operator to page 7234.

For such research-related injuries you can receive emergency care from the
Department of Veteran Affairs, free of charge. Further care will be based on your VA
eligibility.
You understand that the Jerry L. Pettis VA Medical Center will pay for reasonable
non-reimbursed medical expenses you may incur as a direct result of participation in the
study. No other provision has been made for financial payments or other forms of
compensation (such as for lost wages, lost time, or discomfort) due to research-related
injury. You do not, however, waive any legal rights by signing this consent form.
If you wish to contact an impartial third party not associated with this study, or have
questions or concerns about the research or my rights as a research subject, you may contact
the Administrative Officer, Office of Research Administration, Jerry L. Pettis VA Medical
Center, Loma Linda, CA 92357, telephone (909) 422-3050.
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11.

Research subject’s rights:

I have read or have had read to me all of the above. The study has been explained
to me and all of my questions answered. I have been told of the risks or discomforts,
possible benefits of the study, and other choices of treatment available to me.
I understand my rights as a research subject and voluntarily consent to
participate in this study. I understand what the study is about, and how and why it is
being done. I will receive a signed copy of this consent form.

Signature of Subject

Date

Signature of Subject’s Representative *
Representative (print name)

Subject’s

Signature of Witness

Witness (print name)

Signature of Investigator

*Only required if subject not competent.
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Appendix F
Demographic Instrument

LID#:
Peripheral vascular disease 1 2

3.DOB

2. Age:

Arthritis 1 2
4.Sex: 1.M2.F

Dyslipidemia 1 2

5.Marital Status:

GI disease 1 2
Cancer 1 2

l.S 2.M 3.SEP 4.D 6.W
6.Education:
1.

8th grade or less

5. Some College

2.

9-11 grade

6. College Degree

3.

High school graduate

4. Vocational training

10. COPD stage: II ( ) III ( )
Date

ll.FEVi:
l.(ml)

7. Graduate work

2. Predicted (%)

7.Ethnicity:

12. Ejection Fraction (CHF):

1 .African-American 4. Hispanic
2. Asian

13. NYAH A Classification (CHF):

5. Other
1. II

3.Caucasian

8 .Principal Diagnosis:
l.COPD

2.

2. Ill

3.

3.IV

14. Smoking history:

2. CHF Date:

Non-smoker 1

9. Comorbid conditions: Yes 1 No 2

Former smoker 2

Angina 1 2
Prior MI 1 2

Current smoker 3

Prior coronary vascularization 1 2
15. Pack/day/year:

Valvular heart disease 1 2
Hypertension 1 2
Diabetes 1 2
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Date:

UNiVERSi 1 Y LIBRARY
LOMA LINDA, CALIFORNIA
23.c Atenolol 1 2

Pulmonary Medications:

24. Diuretic 1 2

16. Agonist 1 2
16.a Albuterol 1 2

24.a Furosemide 1 2

16.b Albuterol oral 1 2

24.b Metolazone 1 2

16.c Alupent 1 2

24.c HCTZ 1 2
25. Antigoagulant 1 2

16.d Serevent 1 2
17. Ipratroprium 1 2

23.a Warfarin 1 2

18. Theophyline 1 2

23.b ASA 1 2
23.c Clopedoquel 1 2

IS.aUniphill 2

26. Antilipemic 1 2

18.b. Qualtest 1 2

26.a Simivastatin 1 2

19. Steroids inhaled 1 2

27. Antiarrhytmic 1 2

19.aAerobid 1 2

Amiodarone 1 2

19.b Azmacort 1 2

28. Inotropic 1 2

19.cFloventl 2

28.aDigoxinl 2

19.d Vanceril 1 2

29. KCL1 2

20. Steroid Oral 1 2
Dosage:

30. Others

mg/day

31. Antibiotics 1 2

Cardiac Medications:

Name

21. Calcium Channel Blockers 1 2

32. Oxygen: Yes 1 No 2
Frequency:
32.a Continuous 1 2

1/min

21.a Lisinopril 1 2

32.b Night only 1 2

1/min

21.b Fosinopril 1 2

32.c Exercise only 1 2

1/min

21.a Amiodipine 1 2
22. ACE Inhibitors 1 2

23. Beta Blockers 1 2
23.a Carvedilol 1 2
23.b Metoprolol 1 2
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